Q2 --12-31 0001881551 false http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 0001881551 2026-01-01 2026-06-30 0001881551 2026-07-31 0001881551 2026-07-31 2026-07-31 0001881551 sti:SubleaseTwoThousandTwentyNinePeriodMember 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentyNinePeriodMember 2026-06-16 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentyEightPeriodMember 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentyEightPeriodMember 2026-06-16 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentySevenPeriodMember 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentySevenPeriodMember 2026-06-16 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentySixPeriodMember 2026-06-16 0001881551 sti:SubleaseTwoThousandTwentySixPeriodMember 2026-06-16 2026-06-16 0001881551 sti:SubleaseFiveMonthPeriodMember 2026-06-16 0001881551 sti:SubleaseFiveMonthPeriodMember 2026-06-16 2026-06-16 0001881551 sti:PlacementAgentWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember 2026-06-30 0001881551 sti:AwardsWithMarketBasedConditionsMember 2026-01-01 2026-06-30 0001881551 sti:AwardsWithMarketBasedConditionsMember 2026-06-30 0001881551 sti:ForwardPurchaseAgreementMember sti:SeriesDMember 2025-01-01 2025-06-30 0001881551 sti:ForwardPurchaseAgreementMember sti:SeriesCMember 2025-04-01 2025-06-30 0001881551 sti:SeriesDMember 2025-01-01 2025-06-30 0001881551 sti:SeriesCMember 2025-04-01 2025-06-30 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:WarrantSeriesAMember 2026-06-30 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:WarrantSeriesAMember 2026-04-01 2026-06-30 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:WarrantSeriesAMember 2026-03-31 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:WarrantSeriesAMember 2026-01-01 2026-03-31 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:WarrantSeriesAMember 2025-12-31 0001881551 sti:SeriesAWarrantsMember 2026-06-30 0001881551 sti:SeriesAAndBWarrantsMember 2026-06-30 0001881551 sti:SeriesBWarrantsMember 2026-06-30 0001881551 sti:SeriesAAndBWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:SeriesAAndBWarrantsMember 2026-04-01 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2026-06-30 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2026-06-30 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2026-04-01 2026-06-30 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2026-03-31 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2026-01-01 2026-03-31 0001881551 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2025-12-31 0001881551 sti:DerivativesMember 2026-01-01 2026-06-30 0001881551 sti:DerivativesMember 2026-04-01 2026-06-30 0001881551 2026-06-30 0001881551 us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001881551 us-gaap:MeasurementInputExpectedDividendRateMember 2026-06-30 0001881551 us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001881551 us-gaap:MeasurementInputPriceVolatilityMember 2026-06-30 0001881551 us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001881551 us-gaap:MeasurementInputExpectedTermMember 2026-06-30 0001881551 us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001881551 us-gaap:MeasurementInputSharePriceMember 2026-06-30 0001881551 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001881551 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2026-01-01 2026-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember 2025-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:SeriesAWarrantsMember 2026-06-30 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2025-12-31 0001881551 us-gaap:FairValueInputsLevel3Member sti:ForwardPurchaseAgreementMember 2026-06-30 0001881551 sti:OperatingExpensesMember 2026-01-01 2026-06-30 0001881551 sti:OperatingExpensesMember 2025-04-01 2025-06-30 0001881551 srt:ExecutiveOfficerMember 2026-01-01 2026-06-30 0001881551 sti:SellingGeneralAndAdministrativeExpenseMember 2025-04-01 2025-06-30 0001881551 sti:SellingGeneralAndAdministrativeExpenseMember 2025-01-01 2025-06-30 0001881551 sti:SellingGeneralAndAdministrativeExpenseMember 2026-04-01 2026-06-30 0001881551 sti:SellingGeneralAndAdministrativeExpenseMember 2026-01-01 2026-06-30 0001881551 srt:MaximumMember 2026-01-01 2026-06-30 0001881551 srt:MinimumMember 2026-01-01 2026-06-30 0001881551 sti:WarrantsMember 2025-01-01 2025-06-30 0001881551 sti:WarrantsMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsMember 2026-06-30 0001881551 sti:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-06-30 0001881551 sti:ResearchAndDevelopmentExpensesMember 2025-04-01 2025-06-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001881551 us-gaap:RestrictedStockUnitsRSUMember sti:OperatingExpensesMember 2026-01-01 2026-06-30 0001881551 sti:OperatingExpensesMember 2026-04-01 2026-06-30 0001881551 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001881551 sti:UnrestrictedCommonStockAwardsMember sti:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-03-31 0001881551 2025-04-01 2025-06-30 0001881551 2026-04-01 2026-06-30 0001881551 2025-01-01 2025-06-30 0001881551 sti:PromissoryNoteMember us-gaap:RelatedPartyMember 2026-06-30 0001881551 sti:PromissoryNoteMember us-gaap:RelatedPartyMember 2026-05-11 2026-05-11 0001881551 sti:PromissoryNoteMember us-gaap:RelatedPartyMember 2026-05-11 0001881551 sti:PromissoryNoteMember us-gaap:RelatedPartyMember 2026-05-07 2026-05-07 0001881551 us-gaap:RelatedPartyMember 2026-05-07 2026-05-07 0001881551 sti:PromissoryNoteMember us-gaap:RelatedPartyMember 2026-05-07 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember 2025-01-01 2025-12-31 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember 2026-01-01 2026-06-30 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember 2025-10-29 2025-10-29 0001881551 sti:PromissoryNoteMember sti:GreatPointCapitalLLCMember 2025-10-29 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2025-12-31 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2025-08-01 2025-08-31 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-11-01 2024-11-30 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2024-04-29 0001881551 sti:PromissoryNoteMember 2025-01-01 2025-12-31 0001881551 sti:PromissoryNoteMember 2026-01-01 2026-06-30 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2025-12-31 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2026-06-30 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2024-02-01 0001881551 sti:PromissoryNoteMember sti:EFHuttonMember 2024-02-01 2024-02-01 0001881551 sti:ConvertibleNotesMember 2026-06-30 0001881551 sti:ConvertibleNotesMember 2025-01-01 2025-03-31 0001881551 sti:ConvertibleNotesMember 2025-03-31 0001881551 sti:ConvertibleNotesMember 2024-01-01 2024-03-31 0001881551 sti:ConvertibleNotesMember 2024-03-31 0001881551 sti:ForwardPurchaseAgreementMember 2025-01-01 2025-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2025-04-01 2025-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2026-01-01 2026-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2026-04-01 2026-06-30 0001881551 sti:MonteCarloMember sti:FPAShareMember 2026-06-30 0001881551 sti:ForwardPurchaseAgreementMember 2026-06-30 0001881551 sti:FPAShareMember 2026-01-01 2026-06-30 0001881551 sti:FPAShareMember 2025-01-01 2025-12-31 0001881551 sti:MonteCarloMember 2026-01-01 2026-06-30 0001881551 sti:MonteCarloMember 2025-01-01 2025-12-31 0001881551 2025-01-01 2025-12-31 0001881551 2024-08-29 2024-08-29 0001881551 sti:ForwardPurchaseAgreementMember 2024-08-29 2024-08-29 0001881551 us-gaap:DerivativeMember 2024-08-29 2024-08-29 0001881551 sti:ForwardPurchaseInvestorsMember 2024-08-29 2024-08-29 0001881551 sti:ForwardPurchaseAgreementMember 2024-06-11 2024-06-11 0001881551 sti:ForwardPurchaseInvestorsMember 2024-03-22 2024-03-22 0001881551 sti:ForwardPurchaseAgreementMember 2024-01-17 2024-01-17 0001881551 sti:ForwardPurchaseAgreementMember 2024-02-02 0001881551 sti:ForwardPurchaseAgreementMember 2024-02-02 2024-02-02 0001881551 2024-02-02 0001881551 2024-02-02 2024-02-02 0001881551 us-gaap:CommonClassAMember sti:ForwardPurchaseAgreementMember 2026-06-30 0001881551 sti:TwoThousandTwentySixPrivatePlacementMember 2026-01-01 2026-06-30 0001881551 sti:TwoThousandTwentySixPrivatePlacementMember 2026-06-07 2026-06-07 0001881551 sti:TwoThousandTwentySixPrivatePlacementMember sti:PreFundedWarrantsMember 2026-06-07 0001881551 sti:TwoThousandTwentySixPrivatePlacementMember 2026-06-07 0001881551 sti:PlacementAgentWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember us-gaap:MeasurementInputSharePriceMember 2026-06-30 0001881551 us-gaap:CommonStockMember sti:PlacementAgentWarrantsMember 2026-06-30 0001881551 us-gaap:CommonStockMember sti:PreFundedWarrantsMember 2026-06-30 0001881551 sti:PreFundedWarrantsMember 2026-06-09 2026-06-09 0001881551 sti:PreFundedWarrantsMember 2026-06-09 0001881551 us-gaap:CommonStockMember sti:PreFundedWarrantsMember 2026-06-09 0001881551 sti:TerminationAgreementMember sti:AnsonInvestmentsMasterFundLPAnsonMember us-gaap:CommonStockMember 2026-02-05 2026-02-05 0001881551 sti:SeriesDWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesCWarrantsMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesCAndDMember 2025-01-01 2025-12-31 0001881551 sti:WarrantsSeriesCAndDMember 2025-12-31 0001881551 sti:SeriesDWarrantsMember 2025-01-01 2025-12-31 0001881551 sti:AnsonInvestmentsMasterFundLPAnsonMember 2025-12-08 2025-12-08 0001881551 sti:SeriesCWarrantsMember 2025-10-24 2025-10-24 0001881551 sti:WarrantsSeriesCAndDMember 2025-10-08 2025-10-08 0001881551 sti:SeriesCWarrantsMember 2026-06-30 0001881551 sti:WarrantsSeriesCAndDMember 2026-06-30 0001881551 sti:WarrantsSeriesCAndDMember 2026-01-01 2026-06-30 0001881551 us-gaap:CommonStockMember sti:SeriesAAndBWarrantsMember 2026-06-30 0001881551 sti:SeriesBWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:SeriesAWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:SeriesAWarrantsMember us-gaap:InvestorMember 2025-06-30 0001881551 us-gaap:CommonStockMember sti:SeriesAAndBWarrantsMember 2025-06-30 0001881551 sti:SeriesBWarrantsMember 2025-06-30 0001881551 sti:SeriesAWarrantsMember 2025-06-30 0001881551 sti:SeriesBWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:SeriesAWarrantsMember 2025-01-01 2025-06-30 0001881551 sti:MarchPrivatePlacementMember sti:SeriesAAndBWarrantsMember us-gaap:InvestorMember 2025-05-14 0001881551 sti:SeriesAAndBWarrantsMember 2025-05-14 0001881551 sti:PrivateWarrantsMember 2026-01-01 2026-06-30 0001881551 srt:MaximumMember sti:IPOWarrantsMember 2026-01-01 2026-06-30 0001881551 srt:MinimumMember sti:IPOWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:IPOWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:IPOWarrantsMember 2022-12-31 0001881551 sti:IPOWarrantsMember 2022-01-01 2022-12-31 0001881551 sti:TwoThousandTwentySixPrivatePlacementMember 2026-06-30 0001881551 us-gaap:PrivatePlacementMember 2026-06-07 2026-06-07 0001881551 sti:PreFundedWarrantsMember 2026-06-07 2026-06-07 0001881551 sti:PreFundedWarrantsMember 2026-06-07 0001881551 us-gaap:CommonStockMember sti:SeriesCAndDWarrantsMember sti:AugustPrivatePlacementMember 2026-01-01 2026-06-30 0001881551 us-gaap:PrivatePlacementMember 2024-08-30 2024-08-30 0001881551 us-gaap:PrivatePlacementMember 2024-05-13 2024-05-13 0001881551 us-gaap:PrivatePlacementMember sti:SecuritiesPurchaseAgreementMember 2024-05-13 2024-05-13 0001881551 2025-12-31 0001881551 sti:G3HoldbackSharesMember sti:MergerAgreementMember 2026-01-01 2026-06-30 0001881551 sti:HBCHoldbackSharesMember sti:MergerAgreementMember 2026-01-01 2026-06-30 0001881551 sti:DBoralCapitalLLCMember 2026-06-30 0001881551 sti:DBoralCapitalLLCMember sti:PromissoryNoteMember 2026-06-30 0001881551 sti:TaxLienMember 2026-01-01 2026-06-30 0001881551 us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0001881551 us-gaap:RelatedPartyMember 2026-06-30 0001881551 2026-08-07 0001881551 2026-05-07 2026-05-07 0001881551 2026-01-01 2026-03-31 0001881551 2024-01-01 2024-03-31 0001881551 sti:HBCHoldbackSharesMember sti:MergerAgreementMember 2026-01-01 2026-06-30 0001881551 sti:PrivatePlacementWarrantsMember 2022-12-31 0001881551 2025-06-30 0001881551 2025-01-01 2025-03-31 0001881551 sti:ReverseStockSplitMember 2025-05-12 2025-05-12 0001881551 sti:ReverseStockSplitMember 2025-05-12 0001881551 2025-05-12 2025-05-12 0001881551 us-gaap:StockCompensationPlanMember 2025-01-01 2025-06-30 0001881551 sti:WarrantsSeriesCMember 2025-01-01 2025-06-30 0001881551 sti:WarrantsSeriesAMember 2025-01-01 2025-06-30 0001881551 sti:HBCEarnoutSharesMember 2025-04-01 2025-06-30 0001881551 sti:ArborLakeStrategicCooperationConsultingAgreementMember 2025-04-01 2025-06-30 0001881551 sti:StockbasedCompensationWarrantsMember 2025-04-01 2025-06-30 0001881551 us-gaap:StockCompensationPlanMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesDMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesCMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsSeriesAMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsPrivateMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsPublicMember 2025-04-01 2025-06-30 0001881551 sti:HoldbackSharesMember 2025-04-01 2025-06-30 0001881551 sti:StockbasedCompensationWarrantsMember 2026-01-01 2026-06-30 0001881551 us-gaap:StockCompensationPlanMember 2026-01-01 2026-06-30 0001881551 sti:PlacementAgentWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:WarrantsSeriesAMember 2026-01-01 2026-06-30 0001881551 sti:WarrantsPrivateMember 2026-01-01 2026-06-30 0001881551 sti:WarrantsPublicMember 2026-01-01 2026-06-30 0001881551 sti:HoldbackSharesMember 2026-01-01 2026-06-30 0001881551 us-gaap:CommonStockMember sti:TwoThousandTwentyThreeEquityIncentivePlanMember 2026-02-12 0001881551 us-gaap:CommonStockMember 2026-06-30 0001881551 sti:EquityIncentivePlanMember 2026-06-30 0001881551 sti:PreFundedWarrantsMember 2026-06-07 0001881551 us-gaap:CommonStockMember 2026-06-07 0001881551 us-gaap:OverAllotmentOptionMember 2026-06-30 0001881551 us-gaap:PatentsMember 2026-06-30 0001881551 us-gaap:MachineryAndEquipmentMember 2025-12-31 0001881551 us-gaap:MachineryAndEquipmentMember 2026-06-30 0001881551 us-gaap:BuildingImprovementsMember 2025-12-31 0001881551 us-gaap:BuildingImprovementsMember 2026-06-30 0001881551 us-gaap:BuildingMember 2025-12-31 0001881551 us-gaap:BuildingMember 2026-06-30 0001881551 us-gaap:LandImprovementsMember 2025-12-31 0001881551 us-gaap:LandImprovementsMember 2026-06-30 0001881551 us-gaap:EquipmentMember 2026-06-30 0001881551 us-gaap:LeaseholdImprovementsMember 2026-06-30 0001881551 sti:GlobalGrapheneGroupMember 2024-03-31 0001881551 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2026-01-01 2026-06-30 0001881551 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0001881551 sti:RestatedMember us-gaap:ParentMember 2025-06-30 0001881551 sti:RestatedMember sti:StockSubscriptionReceivableMember 2025-06-30 0001881551 sti:RestatedMember us-gaap:RetainedEarningsMember 2025-06-30 0001881551 sti:RestatedMember us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001881551 sti:RestatedMember us-gaap:ParentMember 2025-04-01 2025-06-30 0001881551 sti:RestatedMember us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001881551 sti:RestatedMember us-gaap:ParentMember 2025-03-31 0001881551 sti:RestatedMember sti:StockSubscriptionReceivableMember 2025-03-31 0001881551 sti:RestatedMember us-gaap:RetainedEarningsMember 2025-03-31 0001881551 sti:RestatedMember us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001881551 sti:RestatedMember us-gaap:ParentMember 2025-01-01 2025-03-31 0001881551 sti:RestatedMember us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001881551 sti:RestatedMember us-gaap:ParentMember 2024-12-31 0001881551 sti:RestatedMember sti:StockSubscriptionReceivableMember 2024-12-31 0001881551 sti:RestatedMember us-gaap:RetainedEarningsMember 2024-12-31 0001881551 sti:RestatedMember us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001881551 srt:ScenarioPreviouslyReportedMember sti:StockSubscriptionReceivableMember 2025-01-01 2025-03-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:ParentMember 2024-12-31 0001881551 srt:ScenarioPreviouslyReportedMember sti:StockSubscriptionReceivableMember 2024-12-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2024-12-31 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001881551 us-gaap:PrivatePlacementMember 2026-06-09 2026-06-09 0001881551 us-gaap:CommonStockMember sti:PreFundedWarrantsMember 2026-06-09 2026-06-09 0001881551 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2026-06-09 2026-06-09 0001881551 us-gaap:CommonStockMember sti:MergerAgreementMember 2025-10-09 2025-10-09 0001881551 us-gaap:CommonStockMember sti:MergerAgreementMember sti:HBCHoldbackSharesMember 2024-02-02 2024-02-02 0001881551 us-gaap:CommonStockMember sti:MergerAgreementMember 2024-02-02 2024-02-02 0001881551 sti:MergerAgreementMember 2024-02-02 2024-02-02 0001881551 2024-12-31 0001881551 sti:StockSubscriptionReceivableMember 2025-06-30 0001881551 us-gaap:RetainedEarningsMember 2025-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001881551 us-gaap:CommonStockMember 2025-06-30 0001881551 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001881551 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001881551 2025-03-31 0001881551 sti:StockSubscriptionReceivableMember 2025-03-31 0001881551 us-gaap:RetainedEarningsMember 2025-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001881551 us-gaap:CommonStockMember 2025-03-31 0001881551 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001881551 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001881551 sti:StockSubscriptionReceivableMember 2024-12-31 0001881551 us-gaap:RetainedEarningsMember 2024-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001881551 us-gaap:CommonStockMember 2024-12-31 0001881551 sti:StockSubscriptionReceivableMember 2026-06-30 0001881551 us-gaap:RetainedEarningsMember 2026-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001881551 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001881551 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001881551 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001881551 sti:StockSubscriptionReceivableMember 2026-04-01 2026-06-30 0001881551 2026-03-31 0001881551 sti:StockSubscriptionReceivableMember 2026-03-31 0001881551 us-gaap:RetainedEarningsMember 2026-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001881551 us-gaap:CommonStockMember 2026-03-31 0001881551 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001881551 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001881551 sti:StockSubscriptionReceivableMember 2026-01-01 2026-03-31 0001881551 sti:StockSubscriptionReceivableMember 2025-12-31 0001881551 us-gaap:RetainedEarningsMember 2025-12-31 0001881551 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001881551 us-gaap:CommonStockMember 2025-12-31 0001881551 us-gaap:RelatedPartyMember 2025-12-31 0001881551 2026-08-05 0001881551 sti:StockSubscriptionReceivableMember 2025-04-01 2025-06-30 0001881551 sti:StockSubscriptionReceivableMember 2025-01-01 2025-03-31 0001881551 sti:AwardsWithMarketBasedConditionsMember 2025-12-31 0001881551 srt:ExecutiveOfficerMember 2025-01-01 2025-06-30 0001881551 sti:WarrantsMember 2026-04-01 2026-06-30 0001881551 srt:ScenarioPreviouslyReportedMember us-gaap:ParentMember 2025-01-01 2025-03-31 0001881551 sti:RestatedMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001881551 sti:RestatedMember sti:StockSubscriptionReceivableMember 2025-01-01 2025-03-31 0001881551 sti:RestatedMember us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001881551 sti:RestatedMember sti:StockSubscriptionReceivableMember 2025-04-01 2025-06-30 0001881551 us-gaap:WarrantMember 2025-12-31 0001881551 sti:PreFundedWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:BeneschFriedlanderCoplanAronoffLLPMember 2026-01-01 2026-06-30 0001881551 sti:UnrestrictedCommonStockAwardsMember 2025-04-01 2025-06-30 0001881551 sti:WarrantsMember 2026-01-01 2026-06-30 0001881551 sti:SeriesCAndDWarrantsMember 2025-12-31 0001881551 sti:SeriesCAndDWarrantsMember 2026-01-01 2026-06-30 0001881551 sti:SeriesCAndDWarrantsMember 2026-04-01 2026-06-30 0001881551 sti:TwoThousandTwentyThreeEquityIncentivePlanMember 2026-04-01 2026-06-30 0001881551 2026-06-07 iso4217:USD iso4217:USD xbrli:shares utr:sqft xbrli:pure xbrli:shares sti:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 001-41323

SOLIDION TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 87-1993879
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification Number)

1900 N. Pearl Street, Suite 1750 Dallas, TX |  | 75201
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (972) 918-5120

13355 Noel Road, Suite 1100, Dallas, TX, 75240

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted and pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ | Accelerated filer | ☐
Non-accelerated filer | ☒ | Smaller reporting company | ☒
| Emerging growth company | ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol |  | Name of each exchange on which registered
Common Stock, par value $0.0001 per share |  | STI |  | The Nasdaq Stock Market LLC

As of August 5, 2026, there were 8,512,771 shares of common stock of the Company issued and outstanding.

SOLIDION TECHNOLOGY, INC.

FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2026

TABLE OF CONTENTS

Part I - FINANCIAL INFORMATION |  | 1
Item 1. | Unaudited Condensed Consolidated Financial Statements |  | 1
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 29
Item 3. | Quantitative and Qualitative Disclosures about Market Risk |  | 37
Item 4. | Controls and Procedures |  | 38
Part II - OTHER INFORMATION |  | 39
Item 1. | Legal Proceedings |  | 39
Item 1A. | Risk Factors |  | 39
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds |  | 39
Item 3. | Defaults Upon Senior Securities |  | 39
Item 4. | Mine Safety Disclosures |  | 39
Item 5. | Other Information |  | 39
Item 6. | Exhibits |  | 40
SIGNATURES |  | 41

i

EXPLANATORY NOTE

On February 2, 2024 (the “Closing Date”), Nubia Brand International Corp., a Delaware corporation (“Nubia” and after the Transactions described herein, the “Combined Company” or “Solidion Technology, Inc.”), consummated the previously announced business combination (the “Closing”) pursuant to a Merger Agreement (as amended on August 25, 2023, the “Merger Agreement”), by and among Nubia, Honeycomb Battery Company, an Ohio corporation (“HBC”), and Nubia Merger Sub, Inc., an Ohio corporation and wholly-owned subsidiary of Nubia (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into HBC (the “Merger,” and the transactions contemplated by the Merger Agreement, the “Transactions”), with HBC surviving such merger as a wholly owned subsidiary of Nubia, which was renamed “Solidion Technology, Inc.” upon Closing.

Unless the context otherwise requires, the “registrant” and the “Company” refer to Nubia prior to the Closing and to the Combined Company and its subsidiaries following the Closing and “HBC” and “Honeycomb” refers to Honeycomb Battery Company and its subsidiaries prior to the Closing and the business of the Combined Company and its subsidiaries following the Closing.

The Company’s common stock, par value $0.0001 per share (the “Common Stock”), is now listed on The Nasdaq Stock Market LLC (“NASDAQ Global”) under the symbol “STI”. The Company’s Public Warrants to purchase Common Stock at an exercise price of $575.00 per share, previously listed under ticker “NUBIW”, were delisted from the Nasdaq and are quoted for trading on The OTC Pink Limited Market under the symbol “STIWW”. Until the Merger, Nubia neither engaged in any operations nor generated any revenue, and based on its business activities, Nubia was a “shell company” as defined under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

ii

PART I - FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unAUDITED)

|  | June 30, 2026 |  |  | December 31, 2025 |
ASSETS |  |  |  |  |  |
Current Assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 27,677,315 |  |  | $ | 204,725 |
Accounts receivable |  |  | 47,105 |  |  |  | 5,110 |
Other receivable |  |  | 302,500 |  |  |  | 302,500 |
Inventory |  |  | 24,430 |  |  |  | 24,430 |
Prepaid expenses |  |  | 123,199 |  |  |  | 170,257 |
Other current assets |  |  | 268,966 |  |  |  | 76,166 |
Total Current Assets |  |  | 28,443,515 |  |  |  | 783,188 |
Property and Equipment, net of depreciation |  |  | 1,926,891 |  |  |  | 2,022,043 |
Patents, net of amortization |  |  | 1,997,407 |  |  |  | 1,991,623 |
Total Assets |  | $ | 32,367,813 |  |  | $ | 4,796,854 |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |  |  |  |  |  |  |  |
Current Liabilities: |  |  |  |  |  |  |  |
Accounts payable and accrued expenses |  | $ | 2,676,939 |  |  | $ | 3,509,936 |
Excise tax payable |  |  | 1,088,515 |  |  |  | 964,463 |
Derivative liabilities |  |  | 4,771,891 |  |  |  | 4,772,600 |
Due to related party |  |  | - |  |  |  | 87,873 |
Short-term notes payable |  |  | 2,003,386 |  |  |  | 2,647,556 |
Short-term notes payable – related party |  |  | 151,775 |  |  |  | - |
Total Liabilities |  |  | 10,692,506 |  |  |  | 11,982,428 |
Commitments and contingencies (Note 6) |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficit): |  |  |  |  |  |  |  |
Preferred stock, $0.0001 par value; 2,000,000 shares authorized; none issued and outstanding |  |  | - |  |  |  | - |
Common stock, $0.0001 par value, 300,000,000 shares authorized, 8,512,771 and 7,465,283 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively |  |  | 851 |  |  |  | 746 |
Additional paid-in capital |  |  | 192,365,464 |  |  |  | 159,027,646 |
Stock subscription receivable |  |  | (3,001,045 | ) |  |  | (2,841,427 | )
Accumulated deficit |  |  | (167,689,963 | ) |  |  | (163,372,539 | )
Total Stockholders’ Equity (Deficit) |  |  | 21,675,307 |  |  |  | (7,185,574 | )
Total Liabilities and Stockholders’ Equity (Deficit) |  | $ | 32,367,813 |  |  | $ | 4,796,854 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unAUDITED)

|  | For the Three Months Ended June 30, |  |  | For the Six Months Ended June 30, |
|  | 2026 |  |  | 2025 (Restated) |  |  | 2026 |  |  | 2025 (Restated) |
Net sales |  | $ | 124,914 |  |  |  | 4,000 |  |  | $ | 210,340 |  |  |  | 4,000 |
Cost of goods sold |  |  | - |  |  |  | 2,327 |  |  |  | 1,696 |  |  |  | 2,327 |
Gross profit |  |  | 124,914 |  |  |  | 1,673 |  |  |  | 208,644 |  |  |  | 1,673 |
Operating Expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 370,802 |  |  |  | 399,542 |  |  |  | 773,189 |  |  |  | 1,752,592 |
Selling, general and administrative |  |  | 1,121,449 |  |  |  | 1,389,255 |  |  |  | 2,577,085 |  |  |  | 3,168,874 |
Total operating expenses |  |  | 1,492,251 |  |  |  | 1,788,797 |  |  |  | 3,350,274 |  |  |  | 4,921,466 |
Operating loss |  |  | (1,367,337 | ) |  |  | (1,787,124 | ) |  |  | (3,141,630 | ) |  |  | (4,919,793 | )
Other Income (Expense) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of derivative liabilities |  |  | (917,780 | ) |  |  | (216,150 | ) |  |  | (356,430 | ) |  |  | 12,201,300 |
Interest income |  |  | 35,130 |  |  |  | 1,886 |  |  |  | 35,321 |  |  |  | 18,157 |
Interest expense |  |  | (153,597 | ) |  |  | (112,471 | ) |  |  | (300,830 | ) |  |  | (218,893 | )
Other (expense) |  |  | (483,172 | ) |  |  | - |  |  |  | (553,855 | ) |  |  | - |
Total other income (expense) |  |  | (1,519,419 | ) |  |  | (326,735 | ) |  |  | (1,175,794 | ) |  |  | 12,000,564 |
Net income (loss) before provision for income taxes |  |  | (2,886,756 | ) |  |  | (2,113,859 | ) |  |  | (4,317,424 | ) |  |  | 7,080,771 |
Provision for income taxes |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net Income (Loss) |  | $ | (2,886,756 | ) |  | $ | (2,113,859 | ) |  | $ | (4,317,424 | ) |  | $ | 7,080,771 |
Weighted average number of shares of common stock outstanding, basic |  |  | 8,357,332 |  |  |  | 3,002,802 |  |  |  | 8,074,545 |  |  |  | 3,002,295 |
Basic net income (loss) per share of common stock |  | $ | (0.35 | ) |  | $ | (0.70 | ) |  | $ | (0.53 | ) |  | $ | 2.36 |
Weighted average number of shares of common stock outstanding, diluted |  |  | 8,357,332 |  |  |  | 3,002,802 |  |  |  | 8,074,545 |  |  |  | 3,377,247 |
Diluted net loss per share of common stock |  | $ | (0.35 | ) |  | $ | (0.70 | ) |  | $ | (0.53 | ) |  | $ | (0.53 | )

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ Equity (DEFICIT)

FOR THE THREE AND SIX MONTHS ENDED June 30, 2026

(UNAUDITED)

|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  | Stock Subscription |  |  | Stockholders’ Equity |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Receivable |  |  | (Deficit) |
Balance at December 31, 2025 |  |  | 7,465,283 |  |  | $ | 746 |  |  | $ | 159,027,646 |  |  | $ | (163,372,539 | ) |  | $ | (2,841,427 | ) |  | $ | (7,185,574 | )
Shares issued upon settlement of warrants |  |  | 240,400 |  |  |  | 24 |  |  |  | (24 | ) |  |  | — |  |  |  | — |  |  |  | — |
Forward Purchase Agreement – subscription receivable discount |  |  | — |  |  |  | — |  |  |  | 78,247 |  |  |  | — |  |  |  | (78,247 | ) |  |  | — |
Discount on short term notes payable |  |  | — |  |  |  | — |  |  |  | 70,000 |  |  |  | — |  |  |  | — |  |  |  | 70,000 |
Stock-based compensation to consultants |  |  | 40,000 |  |  |  | 4 |  |  |  | (4 | ) |  |  | — |  |  |  | — |  |  |  | — |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 277,654 |  |  |  | — |  |  |  | — |  |  |  | 277,654 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,430,668 | ) |  |  | — |  |  |  | (1,430,668 | )
Balance at March 31, 2026 |  |  | 7,745,683 |  |  | $ | 774 |  |  | $ | 159,453,519 |  |  | $ | (164,803,207 | ) |  | $ | (2,919,674 | ) |  | $ | (8,268,588 | )
Shares issued from exercise of Series A Warrants |  |  | 17,088 |  |  |  | 2 |  |  |  | 357,139 |  |  |  | — |  |  |  | — |  |  |  | 357,141 |
Forward Purchase Agreement – subscription receivable discount |  |  | — |  |  |  | — |  |  |  | 81,371 |  |  |  | — |  |  |  | (81,371 | ) |  |  | — |
Private Placement - Issuance of common stock, net of issuance costs |  |  | 750,000 |  |  |  | 75 |  |  |  | 9,721,983 |  |  |  | — |  |  |  | — |  |  |  | 9,722,058 |
Private Placement - Issuance of pre-funded stock purchase warrants, net of issuance costs |  |  | — |  |  |  | — |  |  |  | 20,520,023 |  |  |  | — |  |  |  | — |  |  |  | 20,520,023 |
Issuance of stock purchase warrants |  |  | — |  |  |  | — |  |  |  | 1,938,014 |  |  |  | — |  |  |  | — |  |  |  | 1,938,014 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 293,415 |  |  |  | — |  |  |  | — |  |  |  | 293,415 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,886,756 | ) |  |  | — |  |  |  | (2,886,756 | )
Balance at June 30, 2026 |  |  | 8,512,771 |  |  | $ | 851 |  |  | $ | 192,365,464 |  |  | $ | (167,689,963 | ) |  | $ | (3,001,045 | ) |  | $ | 21,675,307 |

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025

(UNAUDITED) (RESTATED)

|  |  |  |  |  |  |  | Additional |  |  |  |  |  | Stock |  |  | Stockholders’ |
|  | Common Stock |  |  | Paid-in |  |  | Accumulated |  |  | Subscription |  |  | Equity |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Receivable |  |  | (Deficit) |
Balance at December 31, 2024 |  |  | 2,633,956 |  |  | $ | 13,169 |  |  | $ | 101,998,956 |  |  | $ | (122,368,539 | ) |  | $ | (2,545,586 | ) |  | $ | (22,902,000 | )
Shares issued from exercise of Series A Warrants |  |  | 14,755 |  |  |  | 74 |  |  |  | 241,472 |  |  |  | — |  |  |  | — |  |  |  | 241,546 |
Conversion of convertible notes into common stock |  |  | 67,895 |  |  |  | 339 |  |  |  | 527,161 |  |  |  | — |  |  |  | — |  |  |  | 527,500 |
Shares issued to consultants |  |  | 100 |  |  |  | 1 |  |  |  | 670 |  |  |  | — |  |  |  | — |  |  |  | 671 |
Reverse stock split |  |  | — |  |  |  | (13,311 | ) |  |  | 13,311 |  |  |  | — |  |  |  | — |  |  |  | — |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 754,361 |  |  |  | — |  |  |  | — |  |  |  | 754,361 |
Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 9,194,630 |  |  |  | — |  |  |  | 9,194,630 |
Balance at March 31, 2025 |  |  | 2,716,706 |  |  | $ | 272 |  |  | $ | 103,535,931 |  |  | $ | (113,173,909 | ) |  | $ | (2,545,586 | ) |  | $ | (12,183,292 | )
Conversion of convertible notes into common stock |  |  | 200 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Reverse stock split |  |  | (112 | ) |  |  | — |  |  |  | (460 | ) |  |  | — |  |  |  | — |  |  |  | (460 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 203,509 |  |  |  | — |  |  |  | — |  |  |  | 203,509 |
Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,113,859 | ) |  |  | — |  |  |  | (2,113,859 | )
Balance at June 30, 2025 |  |  | 2,716,794 |  |  | $ | 272 |  |  | $ | 103,738,980 |  |  | $ | (115,287,768 | ) |  | $ | (2,545,586 | ) |  | $ | (14,094,102 | )

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

SOLIDION TECHNOLOGY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUdITED)

|  | For the Six Months Ended June 30, |
|  | 2026 |  |  | 2025 (Restated) |
Cash Flows From Operating Activities: |  |  |  |  |  |
Net income (loss) |  | $ | (4,317,424 | ) |  | $ | 7,080,771 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 134,800 |  |  |  | 138,400 |
Stock based compensation |  |  | 571,069 |  |  |  | 957,869 |
Equity compensation expense |  |  | — |  |  |  | 671 |
Non-cash interest expense |  |  | — |  |  |  | 202,920 |
Amortization of debt discount |  |  | 62,562 |  |  |  | — |
Accrued interest on short-term note payable - related party |  |  | 1,775 |  |  |  | — |
Change in fair value of derivative liabilities |  |  | 356,430 |  |  |  | (12,201,300 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | (41,994 | ) |  |  | (4,112 | )
Prepaid expenses |  |  | 47,058 |  |  |  | (139,453 | )
Other current assets |  |  | (192,800 | ) |  |  | (431,608 | )
Accounts payable and accrued expenses |  |  | (847,995 | ) |  |  | 1,118,918 |
Income taxes payable |  |  | — |  |  |  | (6,369 | )
Excise taxes |  |  | 124,052 |  |  |  | 27,296 |
Due to related party |  |  | (12,873 | ) |  |  | — |
Net Cash Used In Operating Activities |  |  | (4,115,341 | ) |  |  | (3,255,997 | )
Cash Flows From Investing Activities: |  |  |  |  |  |  |  |
Purchases of property and equipment |  |  | — |  |  |  | (117,812 | )
Capitalized patent costs |  |  | (45,432 | ) |  |  | (63,686 | )
Net Cash Used In Investing Activities |  |  | (45,432 | ) |  |  | (181,498 | )
Cash Flows From Financing Activities: |  |  |  |  |  |  |  |
Proceeds from issuance of common stock and warrants in connection with the Private Placement |  |  | 34,994,842 |  |  |  | — |
Offering costs for common stock and warrants issuance in connection with the Private Placement |  |  | (2,814,747 | ) |  |  | — |
Proceeds from issuance of common stock from exercise of warrants |  |  | — |  |  |  | 241,546 |
Proceeds from short-term notes payable |  |  | 75,000 |  |  |  | — |
Proceeds from short-term notes payable – related party |  |  | 75,000 |  |  |  | — |
Repayment of short-term notes payable |  |  | (696,732 | ) |  |  | (42,671 | )
Cash used to settle fractional shares |  |  | — |  |  |  | (460 | )
Net Cash Provided By Financing Activities |  |  | 31,633,363 |  |  |  | 198,415 |
Net change in cash |  |  | 27,472,590 |  |  |  | (3,239,080 | )
Cash at beginning of period |  |  | 204,725 |  |  |  | 3,353,732 |
Cash at end of period |  | $ | 27,677,315 |  |  | $ | 114,652 |
Supplemental disclosure |  |  |  |  |  |  |  |
Cash paid for interest expense |  | $ | 95,781 |  |  | $ | 7,329 |
Cash paid for federal income taxes |  | $ | — |  |  | $ | 6,369 |
Supplemental disclosure of non-cash financing activities: |  |  |  |  |  |  |  |
Issuance of Common Stock upon the closing of the Merger |  | $ | — |  |  | $ | 414 |
Issuance of stock purchase warrants |  | $ | 1,938,014 |  |  | $ | — |
Issuance of Common Stock upon cashless exercise of warrants |  | $ | 2 |  |  | $ | — |
Forward Purchase Agreement discount accretion |  | $ | 159,618 |  |  | $ | — |
Debt discount recognized on note payable |  | $ | 85,000 |  |  | $ | — |
Issuance of promissory note in settlement of due to related party |  | $ | 75,000 |  |  | $ | — |
Convertible notes converted to common shares |  | $ | — |  |  | $ | 527,500 |
Reclassification of warrant derivative liability to additional paid-in capital upon exercise of Series A warrants |  | $ | 357,139 |  |  | $ | — |
Capitalized interest to principal balance of short-term note payable |  | $ | — |  |  | $ | 202,920 |
Reverse stock split — reclassification from common stock to additional paid-in capital |  | $ | — |  |  | $ | 13,311 |
Shares issued upon settlement of warrants |  | $ | 24 |  |  | $ | — |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

SOLIDION TECHNOLOGY, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

Solidion Technology, Inc. (the “Company”, “Solidion” or “Solidion Technology”), formerly known as Nubia Brand International Corp. prior to February 2, 2024, was incorporated in Delaware on June 14, 2021 and is an advanced battery technology company focused on the development and commercialization of next-generation battery materials, components, and energy storage solutions. Solidion is headquartered in Dallas, TX, with research and development and manufacturing operations located in Dayton, OH.

On February 2, 2024, Nubia Brand International Corp., a Delaware corporation (“Nubia” and after the Transactions described herein, the “Company”, “Solidion” or “Solidion Technology, Inc.”), consummated the merger (the “Closing”) pursuant to a Merger Agreement, dated February 16, 2023 (as amended on August 25, 2023, the “Merger Agreement”), by and among Nubia, Honeycomb Battery Company, an Ohio corporation (“HBC”), and Nubia Merger Sub, Inc., an Ohio corporation and wholly-owned subsidiary of Nubia (“Merger Sub”). HBC was formerly the energy solutions division of Global Graphene Group, Inc. (“G3”). Pursuant to the Merger Agreement, Merger Sub merged with and into HBC (the “Merger,” and the transactions contemplated by the Merger Agreement, the “Transactions”), with HBC surviving such merger as a wholly owned subsidiary of Nubia, which was renamed “Solidion Technology, Inc.” upon Closing.

In accordance with the Merger Agreement, the Company issued to the HBC stockholders aggregate consideration of 1,400,000 shares of Solidion’s common stock, minus up to 4,000 Holdback Shares, subject to adjustment for any additional interest or penalties related to the G3 Tax Lien (the “Closing Merger Consideration Shares”) at the effective time of the Merger Agreement (the “Effective Time”), plus up to an additional 450,000 shares of Solidion’s common stock (the “Earnout Shares”) upon the occurrence of the following events (or earlier upon a change of control of Solidion but subject to (and only to the extent that) the valuation of Solidion’s common stock implied by such change of control transaction meeting the respective volume weighted average price (“VWAP”), as defined in the Merger Agreement.

On October 9, 2025, the Company issued 450,000 shares of its common stock to G3 pursuant to the earnout provisions of the Merger Agreement. The issuance followed the approval of the Company’s Board of Directors to deem all earnout milestones satisfied in full, after considering the Company’s post-merger capital structure and ongoing shared-services arrangements with G3. Accordingly, the Company has completed its obligations related to the Earnout Arrangement under the Merger Agreement.

The Merger was accounted for as a common control transaction with respect to HBC which is akin to a reverse recapitalization. This conclusion was based on the fact that G3 had a controlling financial interest in HBC prior to the Merger and has a controlling financial interest in Solidion (which includes HBC as a wholly owned subsidiary). Net assets of Nubia were stated at their historical carrying amounts with no goodwill or intangible assets recognized in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Merger with respect to HBC was not treated as a change in control due primarily to G3 receiving the controlling voting stake in Solidion and G3’s ability to nominate a majority of the board of directors of Solidion. Under the guidance in ASC 805 for transactions between entities under common control, the assets and liabilities of HBC and Nubia are recognized at their carrying amounts on the date of the Merger.

Under a reverse recapitalization, Nubia was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of HBC issuing stock for the net liabilities of Nubia, accompanied by a recapitalization.

5

Going Concern

The Company’s financial statements have been prepared under the assumption that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business for the foreseeable future.

Since the Company’s inception, it has experienced recurring net losses and net cash used in operating activities and has generated minimal sales. For the six months ended June 30, 2026, the Company recorded a net loss of $4,317,424, and net cash used in operating activities of $4,115,341. In addition, the Company remains in default of an outstanding promissory note in the principal amount of $1,025,824 due to non-payment of scheduled installments (see Note 10). These conditions previously raised substantial doubt about the Company’s ability to continue as a going concern, as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

On June 9, 2026 the Company completed a private placement of 750,000 shares of common stock and pre-funded warrants to purchase 1,583,000 shares of common stock, for aggregate gross proceeds of approximately $35.0 million (approximately $32.2 million net of placement agent fees and offering expenses) (see Note 7). As of June 30, 2026, the Company had cash and cash equivalents of $27,677,315.

Management has evaluated the Company’s projected operating requirements, including its obligations under the promissory note currently in default, against its existing cash and cash equivalents, and has concluded that the Company has sufficient liquidity to fund its operations and satisfy its obligations as they become due — including repayment of the defaulted note in full, if required — for at least one year following the date these financial statements are issued. Accordingly, the conditions that previously raised substantial doubt about the Company’s ability to continue as a going concern have been alleviated.

Nasdaq Compliance

In addition, on September 8, 2025, the Company notified Nasdaq that, following the resignation of a director on September 3, 2025, its Audit Committee was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires listed companies to maintain an audit committee consisting of at least three independent directors. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain compliance, which extends until the earlier of (i) the Company’s next annual meeting of shareholders or (ii) September 3, 2026.

On June 29, 2026, the Company announced that its annual meeting of stockholders has been scheduled for September 15, 2026. Because the annual meeting will occur after September 3, 2026, the Company’s cure period expires on September 3, 2026. The Company is actively evaluating potential candidates to fill the vacancy on its Audit Committee and intends to regain compliance on or before that date.

Risks and Uncertainties

The Company’s current business activities consist of development and commercialization of battery materials, components, cells, and selected module/pack technologies. The Company faces inherent risks associated with its operations, such as the ongoing development of its technology, marketing, and distribution channels, as well as the enhancement of its supply chain and manufacturing capabilities. Additionally, the need to recruit additional management and key personnel is vital. The success of the Company’s development initiatives and the achievement of profitability hinge on various factors, including its ability to enter potential markets and secure sustainable financing in the future.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, competition from substitute products and larger companies, protection of proprietary technology, ability to maintain distributor relationships and dependence on key individuals.

6

NOTE 2 — CORRECTION OF ERRORS IN PREVIOUSLY REPORTED CONSOLIDATED FINANCIAL STATEMENTS

As described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Company restated its previously issued financial statements to correct errors related to (i) the fair value remeasurement of Series A and Series B derivative warrant liabilities under ASC 815, (ii) the recognition of shares issued and a discounted stock subscription receivable in connection with the Forward Purchase Agreement (“FPA”), and (iii) the calculation of basic and diluted income (loss) per share for 2025 interim periods. See Note 2 of the 2025 Annual Report on Form 10-K for a full description of the restatement.

Impact of the Restatement on Previously Issued Unaudited 2025 Interim Financial Statements

The restatement resulted in adjustments to the Company’s opening stockholders’ equity as of January 1, 2025. The adjustments had no impact on the Company’s statements of operations or cash flows for any previously issued 2025 interim period. The following table presents the impact on stockholders’ equity:

|  | Additional Paid-in Capital |  |  | Accumulated Deficit |  |  | Stock Subscription Receivable |  |  | Total Stockholders’ Equity (Deficit) |
Balance at January 1, 2025 (as previously reported) |  | $ | 93,045,581 |  |  | $ | (115,880,509 | ) |  | $ | (80,241 | ) |  | $ | (22,902,000 | )
Correction of prior-period error – warrant remeasurement |  |  | 5,735,883 |  |  |  | (5,735,883 | ) |  |  | — |  |  |  | — |
Correction of prior-period error – Issuance of FPA shares |  |  | 3,124,379 |  |  |  | (752,147 | ) |  |  | (2,372,232 | ) |  |  | — |
Correction of prior-period error – FPA subscription receivable discount |  |  | 93,113 |  |  |  | — |  |  |  | (93,113 | ) |  |  | — |
Balance at January 1, 2025 (as restated) |  |  | 101,998,956 |  |  |  | (122,368,539 | ) |  |  | (2,545,586 | ) |  |  | (22,902,000 | )
Net income |  |  | — |  |  |  | 9,194,630 |  |  |  | — |  |  |  | 9,194,630 |
Balance at March 31, 2025 |  |  | 103,535,931 |  |  |  | (113,173,909 | ) |  |  | (2,545,586 | ) |  |  | (12,183,292 | )
Net loss |  |  | — |  |  |  | (2,113,859 | ) |  |  | — |  |  |  | (2,113,859 | )
Balance at June 30, 2025 |  |  | 103,738,980 |  |  |  | (115,287,768 | ) |  |  | (2,545,586 | ) |  |  | (14,094,102 | )

Correction of Diluted Earnings Per Share

Additionally, the diluted net income per share included in quarter one of the 2025 interim financial information was corrected to apply the treasury stock method to outstanding warrants. For the six months ended June 30, 2025, the previously reported diluted net income (loss) per share of $1.33 should have been $(0.53).

7

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements (the “financial statements”) are presented in conformity with US GAAP and pursuant to the rules and regulations of the SEC.

During the periods prior to the Closing date of the Merger, the Company operated as part of G3. Consequently, stand-alone financial statements have not historically been prepared for the Company. The accompanying financial statements have been prepared from G3’s historical accounting records and are presented on a stand-alone basis as if the Company’s operations had been conducted independently from G3. Therefore, the financial statements included herein may not be indicative of the financial position, results of operations, and cash flows of the Company in the future or if the Company had been a separate, stand-alone entity during the periods presented.

The Company’s financial statements have been prepared under the assumption that the Company will continue as a going concern, which contemplates the realization of assets and discharge of liabilities in the normal course of business for the foreseeable future.

The financial statements include the Company entities. All intercompany transactions have been eliminated for consolidation purposes.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the balance sheet which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

8

Segment Reporting

The Company has determined that the Chief Executive Officer is its Chief Operating Decision Maker (the “CODM”). Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company has determined that it operates in one operating segment and one reportable segment, as the CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

The CODM uses consolidated net (loss) as the measure of segment profit or loss. Expense information is also reviewed only at the consolidated level, as presented in the Company’s consolidated statement of operations. Research and development expense has been identified as a significant segment expense, with all other expense lines being considered part of ‘Other segment items.’ Additionally, the CODM evaluates assets on a consolidated basis. As such, the Company reports segment profit or loss, segment expenses, and segment assets on a condensed consolidated basis.

Cash and cash equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of June 30, 2026, cash equivalents consisted of money market funds of $27,535,128. The Company did not have any cash equivalents as of December 31, 2025.

Accounts Receivable, net of Allowance for Credit Losses

Accounts receivables are stated at the amount the Company expects to collect. The Company recognizes an allowance for credit losses to ensure accounts receivables are not overstated due to un-collectability. Bad debt reserves are maintained as warranted for various customers based on a variety of factors, including the length of time the receivables are past due, significant one-time events and historical experience. An additional reserve for individual accounts is recorded when the Company becomes aware of a customer’s inability to meet its financial obligation, such as in the case of bankruptcy filings, or deterioration in such customer’s operating results or financial position. If circumstances related to a customer change, estimates of the recoverability of receivables would be further adjusted. As of June 30, 2026 and December 31, 2025, the Company determined that no allowance was required.

Other Receivable

During the first quarter of 2024, the Company advanced $302,500 to G3 for transaction costs incurred during the Merger. As of June 30, 2026 and December 31, 2025, the outstanding balance of other receivables amounted to $302,500.

Inventory

Inventories are stated at the lower of first-in, first-out cost or net realizable value. The Company writes-down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. The Company writes off obsolete inventories when the Company deems the value to be impaired. As of June 30, 2026 and December 31, 2025, the Company determined that no write off was required.

Property and Equipment, net

Property and equipment are recorded at cost less accumulated depreciation. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life, are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized. The Company reviews long-lived assets, including property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Indicators of impairment may include significant underperformance relative to historical or projected future operating results, changes in the manner or duration of use of the asset, adverse changes in business climate, or plans for disposal or restructuring.

When an impairment indicator is identified, the Company performs a recoverability test by comparing the carrying amount of the asset group to the estimated undiscounted future cash flows expected to be generated by the assets. If the carrying amount exceeds the undiscounted cash flows, an impairment loss is recognized equal to the amount by which the carrying value exceeds the fair value of the asset group. The impairment loss is included in operating results in the period it is determined.

9

Based on its assessments, the Company did not incur any impairment charges for the three and six months ended June 30, 2026 and 2025.

The Company depreciates its property and equipment for financial reporting purposes using the straight-line method over the estimated useful lives of the assets. The estimated useful lives are as follows:

Building |  | 40 years
Building improvements |  | 15 years
Land improvements |  | 15 years
Machinery & equipment |  | 5 years

Property and equipment consisted of the following as of June 30, 2026 and December 31, 2025:

|  | June 30, 2026 |  |  | December 31, 2025 |
Land improvements |  | $ | 60,137 |  |  | $ | 60,137 |
Buildings |  |  | 1,302,401 |  |  |  | 1,302,401 |
Building improvements |  |  | 2,275,583 |  |  |  | 2,275,583 |
Machinery and equipment |  |  | 2,204,815 |  |  |  | 2,204,815 |
Total property and equipment |  |  | 5,842,936 |  |  |  | 5,842,936 |
Less: accumulated depreciation |  |  | (3,916,045 | ) |  |  | (3,820,893 | )
Property and equipment, net |  | $ | 1,926,891 |  |  | $ | 2,022,043 |

Depreciation expense of property and equipment was $47,576 and $95,152, for each of the three and six months ended June 30, 2026 and 2025, respectively.

Patents

The Company capitalizes external costs, such as filing fees and associated attorney fees, incurred to obtain issued patents. The Company’s intangible assets consist of capitalized costs for unissued patents and issued patents. Issued patents are carried at cost less accumulated amortization. Successful patent efforts are amortized over the life of the patent, and unsuccessful efforts are expensed. The issued patents are being amortized over a useful life of 20 years. Amortization of the patent costs commences upon patent issuance.

Net unissued and issued patents were $1,161,366 and $836,041 as of June 30, 2026, respectively; and $1,155,196 and $836,427 as of December 31, 2025, respectively. The Company assesses the carrying value of its intangible assets for impairment each year and when indicators exist that there could be an impairment. Based on its assessments, the Company did not incur any impairment charges for the three and six months ended June 30, 2026 and 2025, respectively. Intangible assets consisted of the following as of June 30, 2026 and December 31, 2025:

|  | June 30, 2026 |  |  | December 31, 2025 |
Issued patents |  |  |  |  |  |
Gross carrying amount |  | $ | 1,625,156 |  |  | $ | 1,585,894 |
Less: accumulated amortization |  |  | (789,115 | ) |  |  | (749,467 | )
Issued patents, net |  |  | 836,041 |  |  |  | 836,427 |
Patents pending (not amortized) |  |  | 1,161,366 |  |  |  | 1,155,196 |
Total intangible assets, net |  | $ | 1,997,407 |  |  | $ | 1,991,623 |

Amortization expense for the patents included in the condensed consolidated statements of operations was $19,824, $39,648, $20,882 and $43,248 for the three and six months ended June 30, 2026 and 2025, respectively. Future amortization expense for the patents over the next five years is anticipated to be approximately $105,000 per year.

10

Offering and Issuance Costs

The Company accounts for deferred offering costs in accordance with SEC Staff Accounting Bulletin Topic 5.A and ASC 340-10-S99-1, under which costs of a proposed or actual offering of securities are deferred and charged against the gross proceeds of the offering upon completion. Costs related to an offering that is abandoned or aborted are charged to other income (expense).

On June 9, 2026, the Company withdrew its Registration Statement on Form S-1 relating to a previously proposed underwritten offering, following the expiration of the Company’s arrangement with its underwriter in April 2026. As a result, the Company charged $549,915 of previously deferred offering costs, including $89,000 of such costs incurred during the three months ended June 30, 2026, to other income (expense) during the three months ended June 30, 2026.

On June 7, 2026, we entered into a securities purchase agreement (the “2026 Purchase Agreement”) with a new institutional investor (the “2026 Investor”), pursuant to which we agreed to issue and sell, in a private placement (the “2026 Private Placement”), (i) 750,000 shares of Common Stock at a purchase price of $15.00 per share and (ii) pre-funded warrants to purchase up to 1,583,000 shares of Common Stock at a purchase price of $14.9999 per pre-funded warrant (the “Pre-Funded Warrants”). Offering costs incurred in connection with the 2026 Private Placement were charged against the gross proceeds as a reduction of additional paid-in capital. See Note 9 for additional information regarding the 2026 Private Placement. As of June 30, 2026, the Company had no deferred offering costs.

Costs directly attributable to the issuance of equity instruments are recorded as a reduction of the related proceeds within additional paid-in capital. When an equity financing includes more than one class of equity instrument, issuance costs are allocated among the instruments based on their relative fair values at issuance; costs allocated to any liability-classified instrument are charged to expense as incurred.

Leases

The Company determines whether an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use assets are recognized as the lease liability, adjusted for lease incentives received and prepayments made. Lease liabilities are recognized based on the present value of remaining lease payments over the lease term. When the Company’s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Leases with an initial lease term of 12 months or less are not recorded on the condensed consolidated balance sheet.

The Company has elected the short-term lease practical expedient under ASC 842, applying it consistently to all leases with an initial term of 12 months or less, which are excluded from the condensed consolidated balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term. The Company had no right-of-use assets or lease liabilities recorded on its condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, respectively.

Foreign Operations

The functional currency of Solidion’s former Taiwan subsidiary is the New Taiwan Dollar. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 830, Foreign Currency Matters, the financial statements of the Company’s Taiwan subsidiary are translated to U.S. dollars using the exchange rates at the balance sheet dates for assets and liabilities, the historical exchange rate for stockholders’ equity accounts and a weighted average exchange rate for revenue, expenses and gains or losses. Foreign currency translation adjustments are accumulated in a separate component of stockholders’ deficit until the foreign business is sold or substantially liquidated. Foreign currency translation adjustments for the periods presented in these financial statements were not material. The Company ceased research and development operations at its Taiwan location during the three months ended March 31, 2025, and the subsidiary has had no significant operations since that date.

Revenue Recognition

Revenue is recognized when a performance obligation has been satisfied by transferring control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products. Revenues are recognized at a point in time when control transfers to customers, which is generally determined when title, ownership and risk of loss pass to the customer.

Research and Development

All research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel expenses, including salaries, benefits, third party technology validation testing, equipment, engineering, maintenance of facilities, data analysis, and materials.

11

Selling, General and Administrative Expenses

Selling, general and administrative expenses represent costs incurred by the Company in managing the business, including salary, benefits, stock-based compensation, sales, insurance, professional fees and other operating costs associated with the Company’s non-research and development activities.

Stock-Based Compensation

The Company has an incentive equity plan, (“2023 Equity Incentive Plan”). Under the terms of the plan, Solidion’s employees, consultants and directors, and employees and consultants of its affiliates, may be eligible to receive awards in the form of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.

The number of shares of common stock initially reserved for issuance under the incentive plan is 190,000. Shares subject to stock awards granted under the incentive plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the incentive plan. The incentive plan also includes an evergreen provision that provides for an automatic annual increase to the number of shares of common stock available for issuance under the incentive plan on the first day of each fiscal year beginning with the 2024 fiscal year, equal to the least of (i) 190,000 shares of common stock, (ii) 5% of the total number of shares of common stock outstanding as of the last day of our immediately preceding fiscal year, or (iii) such lesser amount determined by the plan administrator.

On February 12, 2026, the Company filed a Registration Statement on Form S-8 with the Securities and Exchange Commission registering 1,084,908 shares of common stock issuable under the 2023 Equity Incentive Plan, which became effective upon filing. As of June 30, 2026, 38,000 shares have been granted under the Plan, of which 0 and 6,667 shares were cancelled and returned to the plan during the three and six months ended June 30, 2026, and 483,575 shares remain available for future issuance.

The Company measures stock options and restricted stock unit awards granted to employees, non-employees, and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which is generally the vesting period of the respective award. Options granted under the 2023 Equity Incentive Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. The plan administrator determines the term of stock options granted under the incentive plan, up to a maximum of ten years. Forfeitures are accounted for as they occur.

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Stock-based compensation expense for restricted stock units is measured based on the grant-date fair value of the awards and recognized as expense over the requisite service period, which is generally the vesting period. The Company has elected to use the accelerated attribution method, under which each vesting tranche of an award is treated as a separate award and expensed over its respective vesting period. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated at the grant date and adjusted prospectively, if necessary.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company lacks a sufficient history of company-specific historical and implied volatility information for its common stock. The Company therefore estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price.

The expected term of all of the Company’s stock options has been determined utilizing the “simplified” method. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on its common stock and does not expect to pay any cash dividends in the foreseeable future.

12

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.

The Company files income and franchise tax returns with the United States, Texas, and Ohio. Examinations by the United States and state tax authorities may include questioning the timing and amount of deductions, the nexus of income among various state and local tax jurisdictions and compliance with federal and state tax laws. As of June 30, 2026, all tax years since the 2021 inception year are subject to examination for U.S. federal and state purposes. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

In July 2025, the One Big Beautiful Bill Act (Public Law 119-21) was enacted. The Company recognized the income tax effects of the legislation in the period of enactment in accordance with ASC 740, which did not have a material impact on the Company’s financial statements. The Company continues to evaluate the impact of the legislation on future periods.

Net Income (Loss) per Common Stock

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period.

The calculation of diluted loss per share of common stock does not include potentially dilutive common stock equivalents if their inclusion would be anti-dilutive as of June 30, 2026 and 2025. As such, net loss per common stock is the same for basic and diluted loss per share for the three and six months ended June 30, 2026.

The following table presents potentially dilutive common stock equivalents that have been excluded from the calculation of dilutive loss per share for the three and six months ended June 30, 2025 as their inclusion would be anti-dilutive:

|  | June 30, 2026 |
Holdback Shares |  |  | 4,000 |
Warrants - Public |  |  | 123,500 |
Warrants - Private |  |  | 108,100 |
Warrants - Series A |  |  | 340,315 |
Placement Agent Warrants |  |  | 116,650 |
Stock-based compensation - equity awards |  |  | 6,000 |
Stock-based compensation - warrants |  |  | 12,000 |
Total common stock equivalents excluded from dilutive loss per share |  |  | 710,565 |

13

The following table presents potentially dilutive common stock equivalents that have been excluded in the calculation of dilutive income per share for the three months ended June 30, 2025, as their inclusion would be anti-dilutive.

|  | June 30, 2025 |
Holdback Shares |  |  | 4,000 |
Warrants - Public |  |  | 123,500 |
Warrants - Private |  |  | 108,100 |
Warrants - Series A |  |  | 810,389 |
Warrants - Series C |  |  | 2,461,538 |
Warrants - Series D |  |  | 244,349 |
Stock-based compensation - equity awards |  |  | 38,000 |
Stock-based compensation - warrants |  |  | 12,000 |
Arbor Lake Strategic Cooperation Consulting Agreement |  |  | 40,000 |
HBC Earnout Shares |  |  | 450,000 |
Total common stock equivalents excluded from dilutive loss per share |  |  | 4,291,876 |

The following table presents potentially dilutive common stock equivalents that have been included in the calculation of dilutive income per share for the six months ended June 30, 2025, as their inclusion would be dilutive.

|  | June 30, 2025 |
Warrants - Series A |  |  | 576,540 |
Warrants - Series C |  |  | 1,715,677 |
Stock-based compensation - equity awards |  |  | 32,136 |
Total common stock equivalents included in dilutive income per share |  |  | 2,324,353 |

The Pre-Funded Warrants issued in the 2026 Private Placement are included in the computation of basic net loss per share from their issuance date because the shares of common stock underlying the Pre-Funded Warrants are issuable for nominal consideration ($0.0001 per share) and there are no remaining contingencies or vesting conditions associated with their exercise. The Placement Agent Warrants are excluded from the computation of diluted net loss per share for the periods presented because their effect would be antidilutive.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial institutions, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and money market funds, which are not insured. As of June 30, 2026, the Company’s cash deposits and money market funds were substantially in excess of federally insured limits. The Company has not experienced any losses on these accounts.

Fair Value of Financial Instruments

Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). See Note 13.

Equity-Linked Instruments

The Company evaluates all equity-linked contracts, including warrants and the Forward Purchase Agreement (“FPA”), to determine classification as either equity or liability in accordance with FASB ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and FASB ASC 815, Derivatives and Hedging (“ASC 815”). This assessment considers whether the instruments meet the fixed-for-fixed equity classification criteria and whether any provisions require liability treatment, including potential “net cash settlement” outside of the Company’s control. Instruments that qualify for equity classification are recorded as a component of additional paid-in capital, while those requiring liability classification are measured at fair value, with subsequent changes recorded in earnings. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the FPA and warrants are outstanding.

Warrants

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are recorded at fair value on the date of issuance and remeasured at each balance sheet date thereafter, with changes in fair value recognized in the statement of operations. The Company evaluates each warrant instrument under ASC 815-40 40 to determine whether it is indexed to the Company’s own stock and whether it meets the conditions for equity classification criteria and do not contain provisions that would require liability classification.

14

The Company accounts for the outstanding Series A warrants issued in connection with the March 2024 private placement financing (the “PIPE Warrants”) as liability-classified instruments because certain settlement adjustments prevent them from meeting the fixed-for-fixed equity classification criteria under ASC 815-40. The Company utilizes the Black-Scholes options pricing model to determine the fair value of the Series A and Series B warrants, and a Monte Carlo simulation model to determine the fair value of the Series C and Series D warrants. The resulting fair value is recorded as a derivative liability on the condensed consolidated balance sheets, and with changes in the fair value of the PIPE Warrants recorded as a non-cash other income (expense) within change in fair value of derivative liabilities account on the Company’s condensed consolidated statements of operations. See Notes 8 and 13 for the classification and measurement of the Company’s outstanding warrants.

Forward Purchase Agreement

The Company accounts for the FPA as either equity-classified or liability-classified instruments based on an assessment of the FPA specific terms and applicable authoritative guidance under FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the FPA meets all of the requirements for equity classification under ASC 815, including whether the FPA is indexed to the Company’s own common shares and whether the FPA holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of FPA issuance and as of each subsequent quarterly period end date while the FPA is outstanding.

The Company has determined that the FPA does not meet all of the criteria for equity classification under ASC 815, as the FPA fails the fixed-for-fixed test under ASC 815-40 due to the bi-weekly Reset Price mechanism, the Dilutive Offering Reset provision, and the VWAP Trigger Event, each of which creates variability in the settlement amount that is not purely a function of the Company’s own stock price. Accordingly, the FPA is classified as a liability-classified derivative instrument, recorded at fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. The Company utilizes a Monte Carlo simulation model to determine the fair value of the FPA. The resulting fair value is recorded as a derivative liability on the condensed consolidated balance sheets. The Company records changes in the fair value of the FPA as a non-cash other income (expense) within change in fair value of derivative liabilities account on the Company’s condensed consolidated statements of operations.

Upon the issuance of shares in connection with the FPA, the Company recognizes (i) an increase to APIC measured at the fair value of the FPA at the time of share issuance, (ii) a corresponding stock subscription receivable of equal amount as a contra-equity component within stockholders’ equity (deficit), representing the present value of the consideration receivable for the shares issued, and (iii) a loss on issuance of common stock within Other Income (Expense) representing the difference between the face value of the stock subscription receivable and its present value at the issuance date. The discount between the face value and present value of the stock subscription receivable is accreted using the effective interest method over the remaining term of the FPA, with each period’s accretion recorded as an increase to both the stock subscription receivable and APIC within stockholders’ equity (deficit). The stock subscription receivable is presented as a reduction to total stockholders’ equity (deficit) and is relieved as Optional Early Termination proceeds are received from the Forward Purchase Investor.

Reverse Stock Split

On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. As a result, each 50 shares of common stock issued and outstanding immediately prior to the reverse split were converted into one share of common stock. Additionally, this transaction resulted in a reclassification of $13,311 from common stock to additional paid-in capital during the three months ended March 31, 2025. The reverse stock split did not change the total number of authorized shares or the par value of the common stock. During the three month period ended June 30, 2025, the Company paid cash of approximately $460 to shareholders in lieu of issuing fractional shares.

In accordance with SEC Staff Accounting Bulletin Topic 4C, all share and per-share amounts in the accompanying condensed consolidated financial statements and notes have been retroactively adjusted to reflect the reverse stock split for all periods presented.

Recently Issued Accounting Standards

In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures by providing more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements and related disclosures.

15

In December 2025, the FASB issued ASU 2025-10, “Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities,” which establishes comprehensive guidance under U.S. GAAP for the recognition, measurement, presentation, and disclosure of government grants received by business entities. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the effect this standard may have on its condensed consolidated financial statements and related disclosures in light of its government grant activity.

In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements,” which clarifies the applicability of the interim reporting guidance, improves the organization and navigability of the interim disclosure requirements, and introduces a disclosure principle requiring entities to disclose events occurring after the most recent annual reporting period that have a material effect on the entity. The ASU is effective for public business entities for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. Entities may apply the amendments prospectively or retrospectively to any or all prior interim periods presented. The Company is currently evaluating the effect this standard may have on its condensed consolidated financial statements and related disclosures.

NOTE 4 — RECAPITALIZATION

IPO warrants

In connection with Nubia’s initial public offering in 2022, 123,500 public warrants and 108,100 Private Warrants were issued, all of which remain outstanding and became warrants for the Common stock in the Company. The Company evaluated the IPO warrants and determined that they are freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the IPO warrants qualify for equity classification.

HBC Holdback Shares

The Company and G3 included a provision in the Merger Agreement that adjusted the aggregate share consideration paid to the shareholders of HBC if the G3 Tax Lien was not released prior to closing. Specifically, 4,000 shares of Solidion common stock, issuable to the HBC shareholders as part of the Merger Consideration were withheld pending settlement of the G3 Tax Lien by G3, subject to adjustment for any additional interest or penalties related to the G3 Tax Lien. See Note 6 for further discussion regarding the Holdback Shares related to the G3 Tax Lien. As of June 30, 2026, the G3 Tax Lien remained unresolved by G3, and the 4,000 holdback shares had not been issued.

NOTE 5 — RELATED PARTIES

Other Receivable

During the three months ended March 31, 2024, the Company advanced $302,500 to G3 for transaction costs incurred during the Merger. The outstanding balance of other receivables amounted to $302,500 as of June 30, 2026 and December 31, 2025.

Shared Services Agreement

Effective February 2, 2024, the Company entered into a shared services agreement (the “SSA”) with G3, under which G3 agreed to provide certain services, including employees, office space and use of equipment, and the Company agreed to pay for such services on a monthly basis. The SSA is subject to typical conditions and may be terminated by either party upon written notice. The management and board continues to monitor the SSA and all other related party transactions to uphold transparency and protect shareholder interests. Expenses incurred related to the SSA services were $60,000 and $123,280 respectively for the six months ended June 30, 2026 and 2025 and $30,000 and $60,692 respectively for the three months ended June 30, 2026 and 2025. Expenses incurred related to the SSA employees were $106,591 and $278,101 respectively for the six months ended June 30, 2026 and 2025 and $53,775 and $81,311, respectively for the three months ended June 30, 2026 and 2025.

There were $0 and $209,979 outstanding as of June 30, 2026 and December 31, 2025, respectively.

16

Due to Related Party

At the time of the merger close, the Company had an outstanding payable related to the monthly administrative services support fees due to Mach FM Corp, an affiliate of Mach FM Acquisitions LLC, the sponsor of Nubia. This fee covered office space, utilities, and secretarial and administrative support provided by Mach FM to support Nubia’s operating activities. Amounts outstanding to Mach FM Corp of $87,873 as of December 31, 2025 were repaid in full during the three months ended June 30, 2026.

Henry Ikezi

Henry Ikezi is a significant stockholder of the Company, beneficially owning approximately 40.5% of the Company’s outstanding common stock through entities under his control, including Madison Bond LLC, Bayside Project LLC, and FUN Investment Homes LLC. Mr. Ikezi does not serve on the Company’s Board of Directors and has no board representation.

Notes Payable — Related Party

During the three months ended March 31, 2026, Madison Bond advanced $75,000 to the Company to fund legal fees incurred. The amount is recorded as a liability in Due to Related Party on the Company’s condensed consolidated balance sheet as of March 31, 2026. On May 11, 2026, the Company formalized the obligation through a promissory note with Madison Bond. The note bears no interest, matures on November 11, 2026, and requires a ballon payment for the entire principal at maturity.

On May 7, 2026, the Company executed a Promissory Note with Madison Bond in the amount of $75,000 in cash for working capital purposes. The note bears interest at 16% per annum and matures on August 7, 2026, with the entire principal due at maturity.

As of June 30, 2026, an aggregate of $151,775 was outstanding under the two promissory notes with Madison Bond, consisting of $150,000 of principal and $1,775 of accrued interest, presented within short-term notes payable - related party on the condensed consolidated balance sheet. No other amounts were due to related parties as of June 30, 2026.

Contingent Consideration

The G3 Tax Lien was not settled by G3 at Closing and, as of June 30, 2026, remained unresolved; accordingly, the 4,000 Holdback Shares have not been issued. The Holdback Shares represent contingent consideration that would become issuable to the HBC shareholders only upon settlement of the G3 Tax Lien by G3. See Note 4 for further discussion regarding the Holdback Shares related to the G3 Tax Lien. As of the Closing Date, the Company recorded a fair value of $906,000 for the 4,000 Holdback Shares, which was accounted for as an equity transaction.

Waiver of Rights under 2024 Securities Purchase Agreement

On June 7, 2026, the Company entered into a waiver (the “Waiver”) with Bayside Project LLC and Madison Bond LLC, each a significant stockholder of the Company, of certain restrictive provisions, pre-emptive and anti-dilution rights, and notice obligations under the securities purchase agreement dated as of August 30, 2024, as amended, among the parties, in order to permit the Company to complete the 2026 Private Placement (see Note 9). The Company did not pay any consideration in connection with the Waiver.

NOTE 6 — COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may be involved in lawsuits, claims or legal proceedings that arise in the ordinary course of business, including proceedings related to the Company’s obligation to register shares for public offering. The Company accrues a contingent liability when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Management believes that there are no claims against us for which the outcome is expected to have a material effect on our financial position, results of operations or cash flows.

D. Boral Capital LLC

In June 2026, D. Boral Capital LLC (f/k/a EF Hutton LLC) (“D. Boral”) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, asserting claims arising from the Company’s default under the Promissory Note described in Note 10. The complaint seeks payment of the outstanding principal of $1,025,824, accrued interest at the default rate of 24% per annum, and costs and disbursements. The Company has recorded the full amount of the outstanding principal and accrued default interest, totaling approximately $1,385,647 as of June 30, 2026, in its condensed consolidated balance sheet. The Company does not believe the resolution of this matter will result in a loss materially in excess of the amounts accrued; however, the outcome of litigation is inherently uncertain, and the Company may incur additional costs, including legal fees and any costs or fees awarded to the plaintiff, that are not currently estimable.

17

G3 Tax Lien

The Internal Revenue Service has placed a federal tax lien on all the property and rights to property belonging to G3 which would include any proceeds from sale of property assets included in the financial statements of the Company. The lien relates to unpaid federal income taxes for 2017. Inclusive of interest, the balance owed is approximately $2,250,000 as of June 2026.

As disclosed in Note 4, the Company and G3 included a provision in the Merger Agreement that adjusts the aggregate share consideration to be paid to the shareholders of HBC if the G3 Tax Lien is not released prior to closing. Specifically, 4,000 shares of Solidion common stock, issuable to the HBC shareholders as part of the Merger Consideration at or following closing, will depend on whether the G3 Tax Lien has been settled by G3 prior to closing. As of the Merger closing and the six months ended June 30, 2026, the G3 Tax Lien remained unsettled by G3 and as of June 30, 2026, the 4,000 holdback shares have not been issued.

The G3 Tax Lien represents a potential obligation that would become payable only upon the sale of the building. As the timing and likelihood of such a sale are uncertain and there are no immediate plans to sell, the Company has not recorded a liability on the balance sheet for this contingent obligation. Should the Company decide to sell the building in the future, this lien may need to be settled from the proceeds of the sale, which could impact the net cash inflow from such a transaction. The Company will continue to monitor the situation and will recognize a liability in the financial statements if and when it becomes probable that the building will be sold and the lien will need to be satisfied.

NOTE 7 — STOCKHOLDERS’ EQUITY (DEFICIT)

Preferred Stock

The Company is authorized to issue 2,000,000 shares of preferred stock with a par value of $0.0001 per share. As of June 30, 2026 and December 31, 2025, there were no shares of preferred stock issued or outstanding.

Common Stock

The Company is authorized to issue 300,000,000 shares of common stock with a par value of $0.0001 per share. Holders of common stock are entitled to one vote for each share. As of June 30, 2026 and December 31, 2025, there were 8,512,771 and 7,465,283 shares of common stock issued and outstanding, respectively.

Equity Financing

On March 13, 2024, Solidion entered into a private placement transaction (the “March Private Placement”), pursuant to a Securities Purchase Agreement (the “March Subscription Agreement”) with certain institutional investors (the “Purchasers”) for aggregate gross proceeds of $3,850,000. As part of the March Private Placement, the Company issued an aggregate of 102,667 units consisting of common stock and Series A and Series B Warrants.

On August 30, 2024, the Company entered into a private placement transaction (the “August Private Placement”), pursuant to a Securities Purchase Agreement (the “August Subscription Agreement”) with certain institutional investors (the “Purchasers”) for aggregate gross proceeds of $4,000,000.

As part of the August Private Placement, the Company issued an aggregate of 244,349 units consisting of common stock and Series C and Series D Warrants. As of December 31, 2025, all Series C and Series D Warrants had been converted into or exchanged for shares of common stock and no warrants remained outstanding.

The Company accounts for the outstanding PIPE Warrants as liability-classified instruments because certain settlement adjustments prevent them from meeting the fixed-for-fixed equity classification criteria under ASC 815-40. The Company utilizes a Monte Carlo simulation model to determine the fair value of the PIPE Warrants. The resulting fair value is recorded as a Derivative liability on the condensed consolidated balance sheets, and records changes in the fair value of the PIPE Warrants as a non-cash other income (expense) within Change in fair value of derivatives account on the Company’s condensed consolidated statements of operations.

On June 7, 2026, the Company entered into a securities purchase agreement with an institutional investor providing for the sale, in a private placement, of 750,000 shares of common stock and Pre-Funded Warrants to purchase up to 1,583,000 shares of common stock, for aggregate gross proceeds of approximately $35.0 million. The 2026 Private Placement closed on June 9, 2026, and the 750,000 shares are included in shares issued and outstanding as of June 30, 2026. See Note 9 for a description of the 2026 Private Placement and Note 8 for the terms of the Pre-Funded Warrants and the Placement Agent Warrants issued in connection therewith.

18

NOTE 8 — WARRANTS

IPO Warrants – Public Warrants

In connection with Nubia’s initial public offering in 2022, 123,500 public warrants were issued, entitling holders to purchase one share of common stock at an exercise price of $575.00 per share, subject to adjustment. Only whole warrants may be exercised. The warrants expire five years after the completion of the Company’s initial business combination on February 2, 2029.

The Company is not obligated to issue shares upon warrant exercise unless a registration statement covering the underlying shares is effective. If a registration statement is not effective, holders may exercise warrants on a cashless basis under certain conditions. The Company may redeem the warrants at $0.50 per warrant, with at least 30 days’ prior notice, if the common stock trades at or above $900.00 per share for 20 trading days within a 30-day period after the warrants become exercisable. Adjustments to the number of shares issuable upon exercise and the exercise price may occur in the event of stock splits, dividends, reorganizations, or similar events. Warrants do not provide voting rights or shareholder privileges until exercised. No fractional shares will be issued upon exercise.

The Company evaluated the public warrants and determined that it is a freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the IPO warrants qualify for equity classification.

IPO Warrants – Private Warrants

In connection with Nubia’s initial public offering in 2022, 108,100 Private Warrants were issued.

Except as described below, the Private Warrants have terms and provisions that are identical to those of the public warrants, including as to exercise price, exercisability and exercise period. The Private Warrants will be exercisable on a cashless basis and will not be redeemable by us so long as they are held by the holders of the private warrants or their permitted transferees. The holders of the Private Warrants or their permitted transferees have the option to exercise the private warrants on a cashless basis. If the Private Warrants are held by holders other than the holders of the Private Warrants and their permitted transferees, the Private warrants will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the units being sold in the Company’s initial public offering.

If exercised on a cashless basis, holders will receive shares of common stock based on the difference between the warrant exercise price and the fair market value of the stock. Fair market value is determined as the average last sale price of the common stock over the 10 trading days ending on the third trading day before the exercise notice date. The reason that The Company have agreed that these warrants will be exercisable on a cashless basis so long as they are held by the holders of the Private Warrants and their permitted transferees is because it is not known at this time whether they will be affiliated with us following an initial business combination. If they remain affiliated with us, their ability to sell the Company’s securities in the open market will be significantly limited. The Company has policies in place that prohibit insiders from selling the Company’s securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell the Company’s securities, an insider cannot trade in the Company’s securities if he or she is in possession of material non-public information. Accordingly, unlike public stockholders who typically could sell the shares of common stock issuable upon exercise of the warrants freely in the open market, the insiders could be significantly restricted from doing so. As a result, The Company believes that allowing the holders to exercise such warrants on a cashless basis is appropriate.

In addition, holders of the Company’s Private Warrants are entitled to certain registration rights.

The Company evaluated the Private Warrants and determined that it is a freestanding equity-linked contract within the scope of ASC 815-40. Based on this guidance, the Company concluded that the Private Warrants qualify for equity classification.

Series A and Series B Warrants

The Series A and Series B Warrants issued in conjunction with the March Private Placement were determined to be liability classified in accordance with ASC 815 and have been recognized at fair value upon issuance, with remeasurement in each subsequent period. As such, on the date of issuance the Company allocated the proceeds between the common stock, Series A Warrants and Series B Warrants first to the fair value of the Series A Warrants and Series B Warrants, which were recorded as a liability.

19

On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. Following the reverse split, the 5-day reset period ended on May 19, 2025, with the lowest 5-day VWAP on May 14, 2025, being $3.0951. Consequently, the reset price was established at $3.0951, and the Series A Warrants held by investors were reset to 810,389 shares. The Series B Warrants were not subject to a post-split reset because no Series B Warrants were outstanding at the time the reverse stock split became effective.

The fair value of the Series A and Series B Warrants as of June 30, 2025, was $2,787,750 and $0, respectively, resulting in a gain of $2,167,550 during the six months ended June 30, 2025. The $0 fair value for the Series B Warrants reflects that all Series B Warrants had been exercised by this date. As of June 30, 2025, 289,613 Series A Warrants and 114,992 Series B Warrants were exercised, resulting in the issuance of 404,605 common shares. As of June 30, 2025, 810,389 Series A Warrants and no Series B Warrants remained outstanding.

The fair value of the Series A and Series B Warrants as of June 30, 2026, was $3,015,191 and $0, respectively. This resulted in a non-cash gain (loss) from the change in fair value of derivatives of $(375,180) and $11,570 for the three and six months ended June 30, 2026, respectively. As of June 30, 2026, investors had exercised 609,476 Series A Warrants and 114,992 Series B Warrants, resulting in the issuance of 687,225 common shares. As of June 30, 2026, 340,315 Series A Warrants and no Series B Warrants remained outstanding.

Series C and Series D Warrants

The Series C and Series D Warrants issued in connection with the August Private Placement were liability-classified in accordance with ASC 815 and remeasured to fair value at each reporting period while outstanding.

On May 12, 2025, the Company effected a 1-for-50 reverse stock split of its common stock. Following the reverse split, the 5-day reset period ended on May 19, 2025, with the lowest 5-day VWAP on May 14, 2025, being the price floor of $3.25. Consequently, the reset price was established at $3.25, and the Series C Warrants held by investors were reset to 2,461,538 shares. The Series D warrants were not subject to a post-split reset based on the terms of the agreement.

On October 8, 2025, Madison Bond LLC and Bayside Project LLC (together, the “New Holders”) purchased all of the outstanding Series C and Series D Warrants previously issued by the Company pursuant to the August Subscription Agreement. Immediately thereafter, the Company exercised its rights under the August Subscription Agreement to convert all remaining unexercised portions of the Series C and Series D Warrants into shares of common stock at a ratio of one share per warrant. On October 24, 2025, the New Holders received 3,447,957 shares of the Company’s common stock.

On December 8, 2025, the Company entered into an agreement with Anson Investments Master Fund LP (“Anson”), pursuant to which it issued 240,400 shares of common stock to Anson in exchange for the termination of all warrants and other obligations of the Company under the Securities Purchase Agreement, dated as of August 30, 2024.

The Company recorded a non-cash loss from changes in the fair value of derivative liabilities related to the Series C and Series D Warrants of $31,033,241 for the year ended December 31, 2025. As of December 31, 2025, investors had exercised 3,688,357 Series C and Series D Warrants, resulting in the issuance of 3,447,957 shares of common stock and the pending issuance of 240,400 shares of common stock and no warrants remained outstanding. Accordingly, no fair value remeasurement was required and no gain or loss from change in fair value was recognized during the three and six months ended June 30, 2026.

The Company recognized non-cash gains from change in fair value of the Series C and Series D Warrants of $1,500,300 and $4,382,250 for the three and six months ended June 30, 2025, respectively.

On February 5, 2026, the Company issued 240,400 shares of common stock to Anson, completing the settlement of all remaining obligations under the termination agreement.

Pre-Funded Warrants

In connection with the 2026 Private Placement (see Note 9), on June 9, 2026 the Company issued Pre-Funded Warrants to purchase up to 1,583,000 shares of common stock. The Pre-Funded Warrants are exercisable at any time after issuance at an exercise price of $0.0001 per share and do not expire until exercised in full. A holder (together with its affiliates) may not exercise any portion of a Pre-Funded Warrant to the extent that, after giving effect to such exercise, the holder would beneficially own in excess of 4.99% (or, at the holder’s election upon issuance, 9.99%) of the Company’s outstanding common stock. The Company evaluated the Pre-Funded Warrants under ASC 815-40 and concluded that they are indexed to the Company’s own stock and meet the conditions for equity classification. Accordingly, the Pre-Funded Warrants were recorded within additional paid-in capital at issuance and are not subject to subsequent remeasurement. As of June 30, 2026, no Pre-Funded Warrants had been exercised and Pre-Funded Warrants to purchase 1,583,000 shares of common stock remained outstanding.

Placement Agent Warrants

Also in connection with the 2026 Private Placement, the Company issued the Placement Agent Warrants to purchase up to 116,650 shares of common stock. The Placement Agent Warrants are immediately exercisable at an exercise price of $17.25 per share (115% of the purchase price per share in the 2026 Private Placement), expire on June 7, 2031, and are subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1). The Placement Agent Warrants provide for customary adjustments in the event of stock dividends, stock splits, reorganizations or similar events. The Company evaluated the Placement Agent Warrants under ASC 815-40 and concluded that they meet the conditions for equity classification. The grant-date fair value of $1,938,014 was estimated using a Black-Scholes option pricing model with the following assumptions: stock price of $20.47, exercise price of $17.25, expected term of 5.0 years, expected volatility of 107.5%, risk-free rate of 4.26%, and expected dividend yield of 0%. The fair value was recognized as an offering cost of the 2026 Private Placement within additional paid-in capital, with no net effect on total stockholders’ equity. The valuation was considered a non-recurring Level 3 fair value measurement.

20

NOTE 9 — FORWARD PURCHASE AGREEMENT AND PRIVATE PLACEMENT FINANCING

2026 Private Placement

On June 7, 2026, the Company entered into a securities purchase agreement with an institutional investor (the “2026 Investor”), pursuant to which the Company agreed to issue and sell, in a private placement, (i) 750,000 shares of common stock at a purchase price of $15.00 per share and (ii) pre-funded warrants to purchase up to 1,583,000 shares of common stock at a purchase price of $14.9999 per Pre-Funded Warrant. The 2026 Private Placement closed on June 9, 2026. The Company received aggregate gross proceeds of approximately $35.0 million and net proceeds of approximately $32.2 million after deducting the placement agent fee of 7% of gross proceeds and other offering expenses. The shares, the Pre-Funded Warrants, and the Placement Agent Warrants (as defined below) were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) thereunder.

Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as sole placement agent. In addition to the cash fee, the Company issued to the placement agent warrants to purchase up to 116,650 shares of common stock (the “Placement Agent Warrants”), representing 5% of the total securities sold at the closing. See Note 8 for the terms and accounting treatment of the Pre-Funded Warrants and the Placement Agent Warrants.

Total offering costs, consisting of cash costs of $2,814,747 and the $1,938,014 grant-date fair value of the Placement Agent Warrants, were allocated between the common stock and the Pre-Funded Warrants issued in the 2026 Private Placement on the basis of their relative fair values at issuance and recorded as a reduction of the gross proceeds within additional paid-in capital. Because both the common stock and the Pre-Funded Warrants are classified within stockholders’ equity, the allocation had no effect on the amounts recognized in the condensed consolidated financial statements, and no offering costs were charged to expense. See Note 3 for the Company’s accounting for offering costs, including the write-off of deferred offering costs associated with a previously proposed offering that was abandoned during the period.

Pursuant to the 2026 Purchase Agreement, the Company agreed to register the resale of the shares and the shares of common stock underlying the Pre-Funded Warrants. The Company filed a registration statement on Form S-1 on June 12, 2026, which was declared effective by the SEC on June 22, 2026. In connection with the 2026 Private Placement, the Company’s directors, executive officers and holders of more than 10% of its common stock (on a fully diluted basis) entered into lock-up agreements restricting sales of the Company’s securities from June 7, 2026 until August 6, 2026 (forty-five days following the effective date of the registration statement), subject to certain exceptions and release with the prior written consent of the placement agent, and the Company agreed to certain restrictions on the issuance and sale of its common stock or common stock equivalents through the same date, subject to customary exceptions. See Note 5 for a waiver obtained from parties to a prior securities purchase agreement in connection with the 2026 Private Placement.

Forward Purchase Agreement

On December 13, 2023, Nubia entered into the FPA with Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP, and Meteora Strategic Capital, LLC (collectively, the “Seller” or “Forward Purchase Investors”). For purposes of the FPA, Nubia is referred to as the “Counterparty” prior to the consummation of the Merger, while Solidion Technology, Inc. (“Pubco”) is referred to as the “Counterparty” after the consummation of the Merger. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the FPA previously filed with the SEC.

Pursuant to the terms of the Forward Purchase Agreement, Seller intends, but is not obligated, to, concurrently with the Closing pursuant to Seller’s FPA Funding Amount PIPE Subscription Agreement, purchase up to 9.9% of the total Class A ordinary shares, par value $0.0001 per share (“Additional Shares”) outstanding following the closing of the Merger, as calculated by Seller (the “Purchased Amount”), less the number of NUBI Shares purchased by Seller separately from third parties through a broker in the open market (“Recycled Shares”). Seller will not be required to purchase an amount of NUBI Shares such that, following such purchase, that Seller’s ownership would exceed 9.9% of the total NUBI Shares outstanding immediately after giving effect to such purchase, unless Seller, at its sole discretion, waives such 9.9% ownership limitation. The Number of Shares subject to the Forward Purchase Agreement is subject to reduction following a termination of the Forward Purchase Agreement with respect to such shares as described under “Optional Early Termination” in the Forward Purchase Agreement.

The FPA provides for a prepayment shortfall equal to 0.50% of the product of Recycled Shares and the Initial Price. The Seller may conduct Shortfall Sales at its discretion to recover this shortfall without triggering early termination obligations. The Prepayment Amount payable to the Seller is calculated based on the number of shares purchased and the redemption price, less any prepayment shortfall, and is funded from the Counterparty’s Trust Account. Additionally, up to 4,000 shares may be purchased at the Initial Price.

Following the Closing, the reset price (the “Reset Price”) was initially the Initial Price. The Reset Price will be subject to reset on a bi-weekly basis commencing the first week following the thirtieth day after the closing of the Merger to be the lowest of (a) the then current Reset Price, (b) the Initial Price and (c) the VWAP Price of the Shares of the prior two weeks; provided the Reset Price shall be subject to reduction upon a Dilutive Offering Reset immediately upon the occurrence of such Dilutive Offering. The Seller also retains the right to terminate part or all of the transaction through Optional Early Termination (OET) by providing notice, with corresponding payment obligations based on the Reset Price.

The Valuation Date for settlement occurs at the earlier of three years post-Merger, specified adverse events (e.g., delisting or registration failure), or at the Seller’s discretion. Upon settlement, adjustments may be made in cash or shares, depending on the circumstances.

21

The Seller has waived redemption rights for Recycled Shares, which may impact the overall redemption levels and market perception of the Merger. The FPA complies with tender offer regulations, including Rule 14e-5 under the Securities Exchange Act of 1934.

On February 2, 2024, upon consummation of the Merger, NUBI made a payment to each Forward Purchase Investor in respect of their respective Recycled Shares. This payment totaled 147 shares and included a cash payment of $80,241 released from the trust account. The payment was calculated as an amount equal to (a) the number of Recycled Shares multiplied by the redemption price per share (the “Initial Price”) as defined in Section 9.2(b) of NUBI’s Certificate of Incorporation, effective as of March 10, 2023, as amended from time to time (the “Certificate of Incorporation”), less (b) the prepayment Shortfall. Additionally, on February 2, 2024, NUBI made a payment to Forward Purchase Investors of $2,193,800 from the trust account as reimbursement for the 4,000 consideration shares.

On January 17, 2024, the Company received a Pricing Date Notice from the Forward Purchase Investors specifying 116,771 Additional Shares. On March 22, 2024, the Company received an amended Pricing Date Notice revising the total number of Additional Shares to 160,771. On June 11, 2024 the Company received an amended Pricing Date Notice revising the total number of Additional Shares to 190,860. On August 29, 2024, the Additional Shares were issued to the Forward Purchase Investors.

Upon the issuance of the 190,860 Additional Shares to the Forward Purchase Investors on August 29, 2024, the Company recognized (i) an increase to APIC of $3,124,379, measured at the fair value of the shares at the time of share issuance, (ii) a corresponding stock subscription receivable of $2,372,232 as a contra-equity component within stockholders’ equity (deficit), representing the consideration receivable for the shares issued, and (iii) a $752,147 loss on issuance of common stock within Other Income (Expense) was recognized representing the difference between the face value of the stock subscription receivable and its present value. The stock subscription receivable is presented as a reduction to total stockholders’ equity (deficit) until the receivable is settled.

The discount of $752,147 is being accreted using the effective interest method over the remaining term of the FPA from August 29, 2024 through February 2, 2027, with each period’s accretion recorded as an increase to both the stock subscription receivable and APIC within stockholders’ equity (deficit), with no impact on the statements of operations. Accretion for the six months ended June 30, 2026 was $159,618. The stock subscription receivable balance as of June 30, 2026 was $3,001,045.

The Company accounts for the FPA as a liability-classified instrument due to the settlement provisions. The resulting fair value is recorded as a derivative liability on the condensed consolidated balance sheets. The Company records changes in the fair value of the FPA as a non-cash other income (expense) within change in fair value of derivatives account on the Company’s condensed consolidated statements of operations.

The Company utilized a Monte Carlo simulation model to determine the fair value of the FPA, comprising Recycled Shares of 147 and Additional Shares of 190,860, totaling 191,007 shares (the “FPA Shares”) as of June 30, 2026 and December 31, 2025. The model estimated the total present value of the Company’s proceeds at $7,670 and the total present value of the Company’s liability at $1,764,383, resulting in a net liability of approximately $1,756,700 as of June 30, 2026.

As a result, the Company recognized non-cash gain (loss) from changes in the fair value of derivatives of $(542,600) and $(368,000) for the three and six months ended June 30, 2026, compared to $381,800 and $5,269,700 for the three and six months ended June 30, 2025.

NOTE 10 —  DEBT

Convertible Notes

At various dates during the first quarter of 2024, the Company issued convertible notes of $527,500 to meet our working capital requirements. At various dates during September and October 2024, the Company and three separate investors amended their respective convertible notes, resulting in a total of approximately an additional 2,707 common shares due upon conversion.

During the three months ended March 31, 2025, holders converted an aggregate of $527,500 principal amount of convertible notes into 67,895 shares of common stock. As of June 30, 2026, convertible notes representing 1,800 shares remained outstanding and subject to conversion.

22

Short-term Notes Payable

D. Boral Capital LLC

On February 1, 2024, the Company executed a Promissory Note with EF Hutton LLC (now known as D. Boral Capital LLC) (“D. Boral”), totaling $2,200,000, to cover underwriters’ fees associated with the closure of the Company’s Merger with HBC. In the case of an event of default, this Note shall bear interest at a rate of 24% per annum until such event of default is cured. The principal amount of this Promissory Note is payable on designated dates, with $183,333 scheduled on the first business day of each month until the final payment on March 1, 2025. As of December 31, 2025, the Company was in default of the Promissory Note due to non-payment of scheduled installments, and the default was continuing as of June 30, 2026. The Promissory Note accrues interest at the default rate of 24% per annum. In June 2026, EF Hutton filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, seeking payment of the outstanding principal, accrued interest, and costs and disbursements. The full amount of principal and accrued default interest is reflected in the Company’s condensed consolidated balance sheet. See Note 6.

The outstanding balance of the Promissory Note amounted to $1,025,824 as of June 30, 2026 and December 31, 2025. The accrued but unpaid interest on the Promissory Note totaled approximately $359,823 and $235,356 as of June 30, 2026 and December 31, 2025, respectively.

Benesch Friedlander Coplan & Aronoff LLP

On April 29, 2024, the Company executed a Promissory Note with Benesch Friedlander Coplan & Aronoff LLP (“Benesch”) in the original principal amount of $670,000, bearing interest at 7% per annum. The note was subsequently amended in November 2024 and August 2025 to, among other things, capitalize unpaid interest, increase the interest rate to 10% per annum, and extend the maturity date to May 31, 2025. The outstanding principal balance was $621,732 as of December 31, 2025, with accrued but unpaid interest of approximately $28,614.

During the three months ended June 30, 2026, the Company repaid the Benesch note in full, including all accrued interest. As of June 30, 2026, no amounts remained outstanding under the note.

Great Point Capital, LLC

On October 29, 2025, the Company executed an unsecured Promissory Note with Great Point Capital, LLC (the “Noteholder”) in the principal amount of $1,000,000. The Note bears interest at a rate of 8.0% per annum, payable quarterly in arrears. The Note matures on October 25, 2026 or the date on which all amounts become immediately due and payable following a Nasdaq delisting notice that would result in the Company’s common stock no longer trading on any Nasdaq market. In the event of a default, the Note bears interest at the Default Rate of 10% per annum.

The Note contains customary representations, warranties, and covenants of the Company and provides for events of default, including nonpayment of principal or interest, breaches of representations, insolvency events, and delisting of the Company’s common stock from Nasdaq. Upon an event of default, the Noteholder may declare all outstanding principal and accrued interest immediately due and payable. The accrued but unpaid interest on the Promissory Note totaled approximately $22,171 and $14,685 as of June 30, 2026 and December 31, 2025, respectively.

The outstanding balance of Short-term Notes Payable amounted to $2,003,386 and $2,647,556 as of June 30, 2026 and December 31, 2025, respectively.

Notes Payable — Related Party

As of June 30, 2026, the Company had two promissory notes outstanding with Madison Bond LLC, a significant stockholder, in the aggregate principal amount of $150,000: (i) a note dated May 7, 2026 in the principal amount of $75,000, bearing interest at 16% per annum and maturing on August 7, 2026, and (ii) a note dated May 11, 2026 in the principal amount of $75,000, bearing no interest and maturing on November 11, 2026, each with the entire principal due in a balloon payment at maturity. Accrued interest on the May 7 note of $1,775 was outstanding as of June 30, 2026. The notes and accrued interest are presented within short-term notes payable - related party on the condensed consolidated balance sheet. No amounts were outstanding under related party notes as of December 31, 2025. See Note 5 for additional information regarding these notes and the Company’s other transactions with Madison Bond.

NOTE 11 — INCOME TAXES

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2026, and December 31, 2025, the Company had a full valuation allowance against its deferred tax assets.

For the three and six months ended June 30, 2026 and 2025, the Company utilized the annualized effective tax rate method and recorded zero income tax expense based on a zero effective tax rate. No tax benefit or expense has been recorded in relation to the pre-tax income for the three and six months ended June 30, 2026 and 2025, and pre-tax losses for the three and six months ended June 30, 2026 and 2025 due to a full valuation allowance to offset any deferred tax assets.

23

NOTE 12 — STOCK-BASED COMPENSATION

Unrestricted Common Stock Awards

During the six months ended June 30, 2026, no unrestricted common stock awards were granted and no related compensation expense was recognized.

During the three months ended March 31, 2025, the Company granted fully vested, unrestricted common shares to certain in connection with the terms of their individual employment agreements and recognized compensation expense of $121,410 in the period. This compensation cost is included within Research and Development expenses on the Company’s condensed consolidated statements of operations for the six months ended June 30, 2025; no such expense was recognized during the three months ended June 30, 2025.

Restricted Stock Units and Stock Options

During the three and six months ended June 30, 2026, no restricted stock units (“RSUs”) were granted. During the three and six months ended June 30, 2026, 0 and 6,667 unvested RSUs were forfeited in connection with management departure, resulting in a reversal of previously recognized compensation cost. The Company recognized the amount of $15,239 and $14,717 in stock-based compensation expense related to RSUs for the three and six months ended June 30, 2026, included within operating expenses on the Company’s condensed consolidated statements of operations.

The following table summarizes RSU activity for the six months ended June 30, 2026:

|  | Number of Shares |  |  | Weighted Average Grant-Date Fair Value |
Outstanding at January 1, 2026 |  |  | 25,333 |  |  | $ | 13.88 |
Granted |  |  | - |  |  |  | - |
Vested |  |  | (12,666 | ) |  |  | 13.88 |
Cancelled |  |  | (6,667 | ) |  |  | 8.17 |
Outstanding at June 30, 2026 |  |  | 6,000 |  |  | $ | 13.88 |

As of June 30, 2026, total unrecognized compensation cost related to unvested RSUs was approximately $72,181, expected to be recognized over a weighted-average period of 0.59 years.

During the six months ended June 30, 2025, the Company granted RSUs to certain executives and management in connection with the terms of their individual employment agreements. The Company recognized the amount of $111,334 and $280,108 for the three and six months ended June 30, 2025, respectively. This compensation cost is included within Research and Development expenses on the Company’s condensed consolidated statements of operations. There were no stock options granted or outstanding during the period ended June 30, 2025.

Warrants

There were no warrants granted during the three and six months ended June 30, 2026. There were 12,000 at-the-money warrants outstanding as of June 30, 2026.

During the three and six months ended June 30, 2025, the Company granted 0 and 12,000 at-the-money warrants, respectively, to certain executive officers pursuant to the terms of their individual employment agreements. The warrants were fully vested upon grant and expire on February 2, 2029, however, the exercise price has not been established.

24

Awards with Market-Based Conditions

In connection with the aforementioned executive employment agreements, certain executives are eligible to receive unrestricted shares of common stock if certain stock price targets are met during the term of the respective employment agreements. A stock price target will be satisfied if the 120-day trailing average closing price (based on trading days) of a share of the Company’s common stock equals or exceeds the applicable stock price target, which range from $1,500 to $15,000 per share. The executives could be granted up to 120,000 shares based on attainment of all applicable stock price targets over the term of six years and an estimated fair value of approximately $4,800,000. The Company recognized $278,176 and $556, 352 of stock-based compensation expense related to these awards for each of the three and six months ended June 30, 2026 and 2025. This compensation cost is included within Selling, General, and Administrative expenses on the Company’s condensed consolidated statements of operations.

The following table summarizes our awards with market-based conditions:

|  | Number of Shares |  |  | Weighted Average Grant-Date Fair Value |
Beginning of period |  |  | - |  |  |  | - |
Granted |  |  | 120,000 |  |  | $ | 40.00 |
Vested |  |  | - |  |  |  | - |
Cancelled |  |  | - |  |  |  | - |
End of period |  |  | 120,000 |  |  | $ | 40.00 |

Awards with Performance Conditions

In connection with the aforementioned executive employment agreements, certain executives are eligible to receive cash incentive payments in connection with the Company achieving certain capital raise targets. In addition, these executives can also receive a cash bonus equal to 2.5% of the equity value of the Company (up to $10 million for each executive, totaling $20 million) in an applicable sale of the Company as defined by the terms of the employment agreements. Through June 30, 2026, it was not considered probable that either performance condition would be achieved, and therefore no expense was recorded related to these awards.

Stock-based Compensation to Consultants

The Company periodically grants equity awards to non-employee consultants and contractors in exchange for services provided to the Company. The Company accounts for these awards in accordance with ASC 718. The grant-date fair value of the awards is measured on the date the awards are approved and the terms of the award and the recipient’s service obligation are established.

Equity awards granted to non-employee consultants and contractors may vest upon the grant date or over a specified service period. The Company recognizes stock-based compensation expense based on the grant-date fair value of the awards over the applicable service period. The grant-date fair value of shares issued is generally based on the closing price of the Company’s common stock on the date of grant.

During the three and six months ended June 30, 2025, the Company recognized stock-based compensation expense of $0 and $671, respectively, related to equity awards granted to consultants and contractors, included within operating expenses. No such expense was recognized during the three and six months ended June 30, 2026.

25

NOTE 13 — FAIR VALUE MEASUREMENTS

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

Level 1—quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3—unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

The following table presents information about the Company’s liabilities that are measured at fair value as of June 30, 2026 and December 31, 2025 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

|  |  |  | June 30, |  |  | December 31, |
Description: |  | Level |  | 2026 |  |  | 2025 |
Derivative Liabilities: |  |  |  |  |  |  |  |
Forward purchase agreement |  | 3 |  | $ | 1,756,700 |  |  | $ | 1,388,700 |
Warrants – Series A |  | 3 |  | $ | 3,015,191 |  |  | $ | 3,383,900 |

Forward purchase agreement

The Company used a Monte Carlo analysis to determine the fair value of the FPA, assuming 191,007 FPA Shares.

The fair value measurement of the FPA at June 30, 2026 and December 31, 2025 was calculated using the following range of weighted average assumptions:

|  | June 30, |  |  | December 31, |
|  | 2026 |  |  | 2025 |
Risk-free interest rate |  |  | 4.00 | % |  |  | 3.48 | %
Stock price |  | $ | 9.29 |  |  | $ | 7.09 |
Expected life |  |  | 0.5 years |  |  |  | 1.1 years |
Expected volatility of underlying stock |  |  | 197.5 | % |  |  | 175.0 | %
Dividends |  |  | 0 | % |  |  | 0 | %

The model measured the total present value of the Company’s proceeds at approximately $7,670 and the total present value of the Company’s liability at approximately $1,764,383, resulting in a net liability of approximately $1,756,700 as of June 30, 2026. This resulted in a non-cash non-operating loss from the change in fair value of derivatives of approximately $542,600 and $368,000 for the three and six months ended June 30, 2026.

26

The following table presents the changes in the fair value of the derivative liability associated with the Forward Purchase Agreement, measured at fair value on a recurring basis using significant unobservable inputs (Level 3), for the three and six months ended June 30, 2026:

|  | Fair Value |
|  | Measurement |
|  | Using Level 3 |
Forward Purchase Agreement |  | Inputs Total |
Balance, December 31, 2025 |  | $ | 1,388,700 |
Change in fair value |  |  | (174,600 | )
Balance, March 31, 2026 |  |  | 1,214,100 |
Change in fair value |  |  | 542,600 |
Balance, June 30, 2026 |  |  | 1,756,700 |

Warrants – Series A and B

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the Series A Warrants at June 30, 2026, which included the following assumptions:

|  | Series A Warrants |
Expected term |  |  | 3.4 years |
Stock price |  | $ | 9.29 |
Risk free rate |  |  | 4.1 | %
Expected volatility |  |  | 184.1 | %
Expected dividend rate |  | $ | 0.00 |
Exercise Price |  | $ | 3.10 |

The fair value of the Series A and Series B Warrants as of June 30, 2026, was $3,015,191 and $0, respectively. The $0 fair value for the Series B Warrants reflects that all Series B Warrants had been exercised by this date. This resulted in a non-cash gain (loss) from the change in fair value of derivatives of $(375,180) and $11,570 for the three and six months ended June 30, 2026, respectively. As of June 30, 2026, investors had exercised 609,476 Series A Warrants and 114,992 Series B Warrants, resulting in the issuance of 687,225 common shares. As of June 30, 2026, 340,315 Series A Warrants and no Series B Warrants remained outstanding.

The following table presents the changes in the fair value of the derivative liability associated with the Series A Warrants, measured at fair value on a recurring basis using significant unobservable inputs (Level 3), for the three and six months ended June 30, 2026:

|  | Fair Value |
|  | Measurement |
|  | Using Level 3 |
Warrants – Series A |  | Inputs Total |
Balance, December 31, 2025 |  | $ | 3,383,900 |
Change in fair value |  |  | (386,750 | )
Balance, March 31, 2026 |  |  | 2,997,150 |
Change in fair value |  |  | 18,041 |
Balance, June 30, 2026 |  |  | 3,015,191 |

27

Warrants – Series C and D

The Company’s Series C and Series D Warrants were classified as derivative liabilities and remeasured to fair value each reporting period until their conversion and cancellation in October 2025 (see Note 8). The Company recognized non-cash gains change in fair value of the Series C and Series D Warrants of $1,500,300 and $4,382,250 for the three and six months ended June 30, 2025, respectively.

Non-cash gains from the change in the fair value of the Series C and Series D Warrants of $1,500,300 and $4,382,250 were recognized for the three and six months ended June 30, 2025, respectively.

As of December 31, 2025, all Series C and Series D Warrants had been exercised and no warrants remained outstanding. Accordingly, no fair value measurement was required for these instruments as of June 30, 2026, and no gain or loss from change in fair value was recognized for the three and six months ended June 30, 2026.

Stock-based compensation – Awards with Market-Based Conditions

The Company utilized a Monte Carlo simulation analysis to determine the fair value of the awards with market-based conditions at the date of the Merger, which included the following assumptions: stock price of $226.50, risk free rate of 3.9%, volatility of 72.5%, dividends yield of 0% and duration of 6 years.

Placement Agent Warrants

In connection with the 2026 Private Placement, the Company issued warrants to the placement agent to purchase up to 116,650 shares of common stock (the “Placement Agent Warrants”), which were classified within stockholders’ equity. Because the Placement Agent Warrants are equity-classified, they are measured at fair value only at issuance and are not remeasured in subsequent periods. Accordingly, the Placement Agent Warrants are not included in the recurring fair value measurement table above.

The grant-date fair value of the Placement Agent Warrants of $1,938,014 was measured on a nonrecurring basis using a Black-Scholes option pricing model, which represents a Level 3 measurement given the significant unobservable inputs. The following assumptions were used: stock price of $20.47, exercise price of $17.25, expected term of 5.0 years, expected volatility of 107.5%, risk-free interest rate of 4.26%, and expected dividend yield of 0%. The fair value was recognized as an offering cost of the 2026 Private Placement within additional paid-in capital, with no net effect on total stockholders’ equity. See Note 8 for additional information.

NOTE 14 — SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, except as noted below, that would have required adjustment or disclosure in the financial statements.

Office lease

In July 2026, the Company entered into a Commercial Sublease Agreement (the “Sublease”) with American State Bank, a Texas banking association, for approximately 3,766 rentable square feet of office space at 1900 N. Pearl Street, Suite 1750, Dallas, Texas 75201, which serves as the Company’s corporate headquarters. The Sublease has a term of 53 months commencing July 13, 2026 and expiring November 30, 2030. Base rent under the Sublease is as follows:

Period |  | Annual Rate (per RSF) |  |  | Monthly Base Rent |  |  | Lease Year
7/13/26 – 11/30/26 |  | $ | 33.83 |  |  | $ | 10,617 |  |  | 1
12/1/26 – 11/30/27 |  | $ | 34.68 |  |  | $ | 10,884 |  |  | 2
12/1/27 – 11/30/28 |  | $ | 35.55 |  |  | $ | 11,157 |  |  | 3
12/1/28 – 11/30/29 |  | $ | 36.44 |  |  | $ | 11,436 |  |  | 4
12/1/29 – 11/30/30 |  | $ | 37.35 |  |  | $ | 11,722 |  |  | 5

In addition to base rent, the Company is obligated to pay its proportionate share of operating expenses, real estate taxes, and landlord insurance (NNN), estimated at $26.76 per rentable square foot for 2026 (approximately $8,404 per month), subject to annual reconciliation. Upon execution, the Company paid a security deposit of $21,906 and prepaid rent of $131,436, which may be applied against future rent obligations one time per calendar quarter beginning December 1, 2027. Total amounts paid to the Sublessor upon commencement, including the security deposit, prepaid rent, and prorated July 2026 rent and NNN, were $165,420.

The Company has determined that the Sublease constitutes an operating lease under ASC 842, Leases. The total undiscounted future minimum base rent payments over the 53-month term are approximately $1,135,146. The right-of-use asset and corresponding lease liability will be recognized on the Company’s condensed consolidated balance sheet as of the commencement date of July 15, 2026 and will be reflected in the Company’s financial statements for the period ending September 30, 2026.

28

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Solidion Technology, Inc. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

Overview

Solidion Technology, Inc. is an advanced battery technology company focused on the development and commercialization of next-generation battery materials, components, and energy storage solutions. Headquartered in Dallas, Texas, with research and development (R&D) and manufacturing operations in Dayton, Ohio, Solidion is dedicated to transforming the energy storage landscape by addressing key limitations in current lithium-ion and emerging battery technologies.

The Company specializes in high-performance silicon-rich anode materials, solid-state battery technology, and fire-retardant electrolytes, aiming to enhance the energy density, safety, and cost-effectiveness of lithium-ion batteries. Solidion’s proprietary innovations include graphene-enabled batteries, elastomer-protected electrodes, quasi-solid and solid-state electrolytes, and biochar-derived anode materials, providing sustainable and scalable solutions for the electric vehicle (EV), energy storage system (ESS), and consumer electronics markets.

Solidion holds an extensive intellectual property (IP) portfolio with over 345 active patents (pending and granted) globally, positioning the Company as a leader in silicon anode and solid-state battery technology. Its innovative silane-free production processes for silicon-based anode materials allow for lower manufacturing costs and improved scalability. Additionally, its fire-retardant and polymer-based electrolytes enable safer, high-energy-density batteries compatible with existing lithium-ion cell production infrastructure.

A key milestone in Solidion’s technological advancements is the successful development of a high-energy cylindrical cell, which achieves an exceptional energy density of 305 Wh/kg, significantly higher than conventional lithium-ion batteries, which typically range between 240-260 Wh/kg. This innovation not only enhances the range and performance of EVs but also underscores Solidion’s ability to deliver cutting-edge solutions for high-energy and high-power applications.

The Company has established strategic partnerships with leading industry players, including Giga Solar Materials Corp. and Bluestar Materials Company, to advance the production and commercialization of silicon oxide (SiOx) anode materials in the U.S. These collaborations, along with Solidion’s ongoing engagement with EV original equipment manufacturers (OEMs) and toll-manufacturing partners, position the Company to accelerate the adoption of its next-generation battery solutions.

Solidion is committed to advancing battery technology through continuous R&D efforts, expanding manufacturing capabilities, and optimizing supply chain sustainability. By integrating cutting-edge materials and scalable production methods, Solidion aims to deliver high-performance, cost-effective, and environmentally sustainable battery solutions that address the increasing demand for electrified mobility and renewable energy storage.

29

Our Products

Anode Materials Our product portfolio includes graphite-based anode materials, distinguished by our commitment to utilizing raw materials from sustainable sources. As part of our efforts to contribute to the goal of net-zero greenhouse gas emissions by 2050, we are scrutinizing our entire supply chain to identify opportunities for reducing environmental impacts. Graphite, a critical component in rechargeable batteries due to its longevity and cost-efficiency, is traditionally derived from petroleum coke and pitch. Solidion’s innovative approach introduces biochar produced from waste biomass as an alternative feedstock. This sustainable process not only sequesters carbon but may also result in carbon-negative production. By leveraging biochar, Solidion aims to produce anode-grade graphite with exceptional performance. By the end of 2024, Solidion’s anode materials containing biochar-derived materials have achieved a capacity of over 340 mAh/g and comparable cycle life to conventional graphite anodes, marking a significant step towards more environmentally responsible battery manufacturing. Solidion has also developed a series of silicon and SiOx anode materials that enable a significantly higher energy density (for example, an expected 20-30% increase in the EV driving range) likely at a reduction in the cell cost in terms of U.S. dollars per kilowatt hour (“kWh”) when production in scale occurs. The specific capacity of these products range from 1,300 to 2,800 mAh/g aiming to suit different applications including EV, energy storage stations, drones, and consumer electronics.

Battery Cells To rigorously validate the performance of its innovative anode materials, Solidion is actively engaged in the development and testing of a diverse portfolio of battery cells. By the close of 2024, Solidion, in collaboration with strategic partners, has successfully constructed and evaluated over three distinct types of cylindrical cells, each featuring either our advanced silicon (Si) or graphite-based anodes. These cells showcase a wide range of capabilities, with capacities spanning from 4.6 to an impressive 5.5Ah.

Notably, our high-energy 5.5Ah 21700 cylindrical cell represents a significant leap forward in battery technology. This cell not only achieves an exceptional energy density of 305 Wh/kg, surpassing the typical 240-260 Wh/kg offered by established Asian manufacturers in the same high-energy category, but also delivers superior power performance. It boasts a continuous charging and discharging capability exceeding 2C, a substantial improvement over the performance less than 1C typically seen in competitor products. This combination of high energy density and robust power handling makes our 5.5Ah cell ideally suited for applications demanding both sustained energy delivery and moderate to high power output, such as advanced electric vehicles and high-performance portable electronics.

Furthermore, Solidion is actively developing cell variants tailored for applications requiring even higher power capabilities. These cells have already demonstrated impressive fast-charging capabilities, exceeding 3C, enabling rapid replenishment of energy and minimizing downtime. This focus on high-power cells underscores our commitment to addressing the diverse needs of the evolving energy storage market.

Beyond anode advancements, Solidion is also pioneering the development of next-generation electrolytes. As previously mentioned, we have successfully formulated fire-retardant and quasi-solid electrolytes, demonstrating their performance through the construction of small prototype cells. These electrolytes represent a significant step towards enhancing battery safety, a critical consideration in today’s demanding applications. Looking ahead, Solidion intends to scale up production of these electrolyte-based cells, manufacturing larger format cells in common practical sizes. This initiative will not only validate the performance of our advanced electrolytes in real-world scenarios but also pave the way for the development of safer and more reliable energy storage solutions. By integrating our innovative anode materials with these advanced electrolytes, Solidion is poised to deliver a new generation of high-performance, safe, and sustainable batteries.

30

Recent Developments

2026 Private Placement

On June 7, 2026, we entered into a securities purchase agreement (the “2026 Purchase Agreement”) with a new institutional investor (the “2026 Investor”), pursuant to which we agreed to issue and sell, in a private placement (the “2026 Private Placement”), (i) 750,000 shares of Common Stock at a purchase price of $15.00 per share and (ii) pre-funded warrants to purchase up to 1,583,000 shares of Common Stock at a purchase price of $14.9999 per pre-funded warrant (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable at any time after issuance at an exercise price of $0.0001 per share and do not expire until exercised in full. Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as sole placement agent for the 2026 Private Placement. The closing of the 2026 Private Placement occurred on June 9, 2026. We received aggregate gross proceeds of approximately $35.0 million and, after deducting the placement agent fee of 7% of gross proceeds and related offering expenses, net proceeds of approximately $32.2 million, which we intend to use to support the commercialization of our patented Extreme-Climate Battery technology, fulfill customer demand, expand inventory, advance the building and testing of prototypes, and for working capital and general corporate purposes.

Pursuant to the 2026 Purchase Agreement, we agreed to file a registration statement with the SEC registering the resale of the shares and the shares of Common Stock underlying the Pre-Funded Warrants. We filed the registration statement on Form S-1 on June 12, 2026, and it was declared effective by the SEC on June 22, 2026. In connection with the 2026 Private Placement, each of our directors, executive officers and holders of more than 10% of our Common Stock (on a fully diluted basis) entered into lock-up agreements restricting sales of our securities from June 7, 2026 until August 6, 2026, forty-five (45) days following the effective date of the registration statement (subject to certain exceptions and release with the prior written consent of the placement agent), and we agreed to certain restrictions on the issuance and sale of our Common Stock or Common Stock equivalents through the same date, subject to customary exceptions.

In connection with the 2026 Private Placement, we issued to the placement agent warrants (the “Placement Agent Warrants”) to purchase up to 116,650 shares of Common Stock, representing 5% of the total securities sold at the closing. The Placement Agent Warrants are immediately exercisable at an exercise price of $17.25 per share (equal to 115% of the purchase price per share in the 2026 Private Placement) and expire on the five-year anniversary of the date of the 2026 Purchase Agreement. The Placement Agent Warrants are subject to a 180-day lock-up from the date of the 2026 Purchase Agreement pursuant to FINRA Rule 5110(e)(1) and contain customary adjustments in the event of stock dividends, splits, reorganizations or similar events.

See Note 9 to the condensed consolidated financial statements for additional information regarding the 2026 Private Placement.

Treasury Strategies

On June 29, 2026, we announced our intention to opportunistically acquire shares of Space Exploration Technologies Corp. (“SpaceX”) to be held as a long-term strategic treasury asset. We expect the initial allocation, and any future additions, to represent a modest portion of our cash on hand and not to interfere with our operating priorities, planned capital expenditures, or ability to fund our core operations and strategic plan. As of June 30, 2026, and through the date of this Quarterly Report, we had not acquired any SpaceX shares under this strategy.

On November 14, 2024, we adopted a strategic Bitcoin allocation policy for our corporate treasury under which, subject to board approval, we may allocate excess cash from operations toward Bitcoin purchases, convert interest earnings from cash held in money market accounts into Bitcoin, and allocate a portion of future capital raises to Bitcoin acquisitions. To date, we have not purchased any Bitcoin under this policy. For fiscal year 2025, we did not identify excess cash from operations available for Bitcoin purchases, and the interest income of $19,094 generated in 2025, which had been designated for Bitcoin purchases, has not yet been converted. We did not allocate any portion of the net proceeds of the 2026 Private Placement to Bitcoin acquisitions, and the proceeds are intended to be used for the purposes described under “2026 Private Placement” above. Any future purchases of Bitcoin, including any conversion of designated interest earnings or allocation of proceeds from future capital raises, remain subject to board approval and will be evaluated in light of our operating priorities and liquidity needs.

Office Lease

In July 2026, we entered into a Commercial Sublease Agreement for approximately 3,766 rentable square feet of office space at 1900 N. Pearl Street, Suite 1750, Dallas, Texas, which serves as our corporate headquarters. The sublease has a 53-month term commencing July 13, 2026 and expiring November 30, 2030, with total undiscounted future minimum base rent payments of approximately $1,135,146, plus our proportionate share of operating expenses, real estate taxes, and landlord insurance. Upon execution we paid a security deposit of $21,906 and prepaid rent of $131,436. See Note 14 to the condensed consolidated financial statements.

31

Memorandum of Understanding

On February 10, 2026, we entered into a non-binding memorandum of understanding (“MOU”) with an entity that manufactures and distributes energy storage systems for the Company to supply pouch cells for use in energy storage systems. While the MOU is non-binding in nature and may result in no actual sales, a definitive agreement could potentially add an estimated $4 to $6 million in revenue over the next 12 months.

Grants from the U.S. Government

During the fourth quarter of 2025 and the first quarter of 2026, the Company was notified that it had received three grants from various departments of the U.S. government. The U.S. Department of Energy (“DOE”) provided the first grant (the “First Grant”), which was to advance research and development of Electrochemical Manufacturing of High-Performance Graphite based on Biomass-Derived Carbon. The Company had received the prestigious 2025 R&D 100 Award in partnership with Oak Ridge National Laboratory for innovation in Electrochemical Graphitization in Molten Salts, and the First Grant was for research to be conducted jointly with Oak Ridge National Laboratory to reduce imports of critical energy materials from foreign sources, improve American energy independence, and ensure that the U.S. maintains a technological lead in developing and deploying advanced energy technologies.

The DOE provided the second grant (the “Second Grant”) to scale up the synthesis of a carbon-nanosphere material that will be used as an anti-corrosive additive in molten-salts-based heat transfer fluids for advanced molten salt nuclear reactors. The Second Grant was also for research to be conducted jointly with Oak Ridge National Laboratory, this time to develop a nanofluids-based energy material, engineered colloidal suspension of hollow carbon nanoparticles in conventional molten salts, to enhance heat transfer and reduce corrosion in nuclear reactors, which is critical for reducing costs, increasing safety, and accelerating the commercialization of small modular nuclear reactors such as advanced molten salt reactors.

The U.S. Army provided the third grant (the “Third Grant”) to develop an advanced fiber-based electronic battery system built on a coaxial carbon nanotube (“CNT”) yarn architecture. The Third Grant was for research to be conducted jointly with The University of Texas at Dallas to develop a flexible, rechargeable lithium-ion battery in fiber form: a CNT yarn serves as both the structural core and current collector of the anode, integrated with Solidion’s silicon (Si) as the high-capacity anode material.

Unregistered Sales of Equity Securities

On December 8, 2025, the Company entered into an agreement with Anson Investments Master Fund LP (“Anson”), pursuant to which it issued 240,400 shares of common stock to Anson in exchange for the termination of all warrants and other obligations of the Company under the Securities Purchase Agreement, dated as of August 30, 2024. Further, Anson agreed to limit sales of common stock to no more than 10% of the daily trading volume on the Nasdaq Stock Market of all of the Company’s common stock. On February 5, 2026, the Company issued the 240,400 shares of its common stock to Anson pursuant to this agreement. The issuance was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to the issuance.

32

Change to Board of Directors

On September 3, 2025 (the “Resignation Date”), Cynthia Ekberg Tsai notified the Board of Directors (the “Board”) of the Company of her resignation as a member of the Board, including all committees on which she serves, effective as of the Resignation Date. Ms. Ekberg Tsai’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

As a result of Ms. Ekberg Tsai’s resignation, the Company’s Audit Committee is composed of two members. On September 8, 2025, the Company notified The Nasdaq Stock Market, LLC of its non-compliance with Nasdaq Rule 5605(c)(2)(A), which requires that the Audit Committee be composed of three directors. Pursuant to Nasdaq Listing Rule 5605(c)(4), the Company has a cure period to regain compliance by appointing a new independent director to the Audit Committee, which extends until the earlier of the Company’s next annual meeting of shareholders or September 3, 2026.

On March 24, 2026, the Company announced an annual meeting of shareholders scheduled for June 11, 2026. On June 29, 2026, the Company announced that the annual meeting has been rescheduled for September 15, 2026. Because the rescheduled annual meeting will occur after September 3, 2026, the Company’s cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) expires on September 3, 2026. The Company is actively evaluating potential candidates to fill the vacancy on its Audit Committee and intends to appoint a new independent director to the Audit Committee on or before that date.

Components of Results of Operations

Revenue

The Company is focused on commercializing and manufacturing battery materials and next-generation battery cells. Historically, and during the periods presented, we have generated minimal revenue from product samples. We do not expect to begin generating significant revenue until we complete the commercialization process and build out manufacturing capacity. Future capacity may come from joint ventures with strategic partners, sourcing third-party manufacturing from our network, or pursuing mergers and acquisitions.

Operating Expenses

Research and Development

Research and development expenses consist primarily of personnel expenses, including salaries, benefits, third party technology validation testing, equipment, engineering, maintenance of facilities, data analysis, and materials.

Selling, General and Administrative

Selling, general and administrative expenses primarily consist of personnel expenses, including salaries, benefits, and stock-based compensation related to executive management, finance, legal, and human resource functions. Other costs include business development, contractor and professional services fees, audit and compliance expenses, insurance costs and general corporate expenses, such as rent, office supplies and information technology costs.

33

Other Income (Loss)

Change in fair value of Derivative Liabilities

Change in fair value of Derivative Liabilities consists of fluctuations in the fair value of an agreement between the Company and investors facilitating future purchases of the Company’s stock by the Investor based on a Monte Carlo simulation model.

Interest Income

Interest income is derived from the Company’s operating cash account, which is periodically invested in short-term money market funds.

Interest Expense

Interest expense consists primarily of the interest on the Company’s short-term notes and D&O insurance premium financing arrangement.

Results of Operations

This data should be read in conjunction with Solidion’s financial statements and accompanying notes. These results of operations are not necessarily indicative of future performance.

Summary of Statements of Operations for the Three Months Ended June 30, 2026 and 2025

|  | For the Three Months Ended June 30, |
|  | 2026 |  |  | 2025 (Restated) |
Net sales |  | $ | 124,914 |  |  | $ | 4,000 |
Cost of goods sold |  |  | - |  |  |  | 2,327 |
Operating expenses |  |  | 1,492,251 |  |  |  | 1,788,797 |
Total other expense |  |  | (1,519,419 | ) |  |  | (326,735 | )
Net loss |  | $ | (2,886,756 | ) |  | $ | (2,113,859 | )

Net Sales

Net sales increased by $120,914 for the three months ended June 30, 2026, to $124,914, compared to $4,000 for the three months ended June 30, 2025. The increase was primarily attributable to government grant revenue recognized during the period.

Operating Expenses

Operating expenses decreased by $296,546 for the three months ended June 30, 2026. This decrease was primarily driven by lower general and administrative costs, including reduced personnel and professional services expenses. Additionally, there were decreased research and development costs, including personnel expenses associated with the commercialization of our battery cell products and third-party validation testing of our proprietary silicon anode.

Other Income (Expense)

Other expense increased by $1,192,684 for the three months ended June 30, 2026. This increase was largely driven by a loss of $917,780 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement and warrants related to the March private placement financing, compared to a loss of $216,150 in the three months ended June 30, 2025. Other expense for the quarter also included a $549,915 non-cash write-off of deferred offering costs associated with a registration statement the Company withdrew in June 2026, and interest expense of $153,597 primarily related to the Company’s short-term notes.

34

Summary of Statements of Operations for the Six Months Ended June 30, 2026 and 2025

|  | For the Six Months Ended June 30, |
|  | 2026 |  |  | 2025 (Restated) |
Net sales |  | $ | 210,340 |  |  | $ | 4,000 |
Cost of goods sold |  |  | 1,696 |  |  |  | 2,327 |
Operating expenses |  |  | 3,350,274 |  |  |  | 4,921,466 |
Total other income (expense) |  |  | (1,175,794 | ) |  |  | 12,000,564 |
Net income (loss) |  | $ | (4,317,424 | ) |  | $ | 7,080,771 |

Net Sales

Net sales increased by $206,340 for the six months ended June 30, 2026, to $210,340, compared to $4,000 for the six months ended June 30, 2025. The increase was primarily attributable to government grant revenue recognized during the period.

Operating Expenses

Operating expenses decreased by $1,571,192 for the six months ended June 30, 2026. This decrease was primarily driven by lower general and administrative costs, including reduced personnel and professional services expenses. Additionally, there were decreased research and development costs, including personnel expenses associated with the commercialization of our battery cell products and third-party validation testing of our proprietary silicon anode.

Other Income (Expense)

Other expense increased by $13,176,358 for the six months ended June 30, 2026. This increase was largely driven by a loss of $356,430 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement, and warrants related to the Private Placement financing, compared to a gain of $12,201,300 in the six months ended June 30, 2025. Additionally, there was interest expense of $300,830 primarily related to the Company’s short-term notes.

Cash Flows

The following tables set forth a summary of our cash flows for the periods indicated:

|  | For the Six Months Ended June 30, |
|  | 2026 |  |  | 2025 (Restated) |
Net cash provided by (used in): |  |  |  |  |  |
Operating Activities |  |  | (4,115,341 | ) |  |  | (3,255,997 | )
Investing Activities |  |  | (45,432 | ) |  |  | (181,498 | )
Financing Activities |  |  | 31,633,363 |  |  |  | 198,415 |
Net increase (decrease) in cash |  |  | 27,472,590 |  |  |  | (3,239,080 | )

Net Cash used in Operating Activities

For the six months ended June 30, 2026, cash used in operating activities was $4,115,341. This primarily resulted from net loss of $4,317,424, which included non-cash loss of $356,430 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement and March Private Placement warrants. These non-cash losses were added back to reconcile net income to net cash used in operating activities, as part of non-cash adjustments that also included depreciation and amortization, stock-based compensation amortization of debt discount and accrued interest related to short-term notes payable – related party, totaling $1,126,636. Additionally, changes in operating assets and liabilities used $911,680 of cash from operating activities, driven primarily by a $847,995 decrease in accounts payable and accrued expenses.

For the six months ended June 30, 2025, cash used in operating activities was $3,255,997. This primarily resulted from net income of $7,080,771, which included non-cash gain of $12,201,300 due to a change in the fair value of derivative liabilities related to the Forward Purchase Agreement and March and August Private Placement warrants. These non-cash gains were added back to reconcile net income to net cash used in operating activities, as part non-cash adjustments that also included depreciation and amortization, stock-based compensation non-cash interest expense, totaling $10,901,440. Additionally, changes in operating assets and liabilities used $564,672 of cash from operating activities, driven primarily by a $431,608 increase in other current assets. The increase in other current assets was due to the financing arrangement associated with the directors and officers insurance policy.

Net Cash used in Investing Activities

For the six months ended June 30, 2026, the Company used cash of $45,432 in investing activities consisting of capitalized patent costs.

For the six months ended June 30, 2025, the Company used cash of $181,498 in investing activities consisting of purchases of Silicon Oxide (SiOx) manufacturing equipment and capitalized patent costs.

35

Net Cash provided by Financing Activities

For the six months ended June 30, 2026, net cash provided by financing activities was $31,633,363. This consisted primarily of net proceeds of approximately $32.2 million from the 2026 Private Placement, after deducting the placement agent fee and offering expenses paid and partially offset by the repayments of short-term notes of $696,732.

For the six months ended June 30, 2025, the Company generated cash of $198,415 from financing activities. The Company received proceeds from warrant exercises of $241,546. These increases were offset by repayment of short-term notes of $42,671.

Liquidity and Capital Resources

Since Solidion’s inception, the Company has experienced recurring net losses and has generated minimal sales. These conditions, together with the Company’s limited cash resources in prior periods and its default under an outstanding promissory note, previously raised substantial doubt about the Company’s ability to continue as a going concern, as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

In June 2026, we completed a private placement of 750,000 shares of common stock and pre-funded warrants to purchase 1,583,000 shares of common stock, for aggregate gross proceeds of approximately $35.0 million (approximately $32.2 million net of placement agent fees and offering expenses).

As of June 30, 2026, we had cash and cash equivalents of $27,677,315. Management has evaluated our projected operating requirements — including our obligations under the promissory note currently in default and — against our existing cash and cash equivalents, and has concluded that we have sufficient liquidity to fund our operations and satisfy our obligations as they become due for at least one year following the date the financial statements included in this Quarterly Report are issued. Accordingly, the conditions that previously raised substantial doubt about our ability to continue as a going concern have been alleviated. See Note 1 to the condensed consolidated financial statements.

During the six months ended June 30, 2026, we incurred losses from operations totaling $4,317,424 and net cash used in operating activities of $4,115,341. As of June 30, 2026, we had an accumulated deficit of $167,689,963. We expect to continue to incur such losses for at least the next twelve months, and we expect our expenditures to increase as we advance our development and commercialization activities. Our longer-term capital requirements will depend on many factors, including the pace of our technology development, the buildout of manufacturing capabilities, and our ability to generate revenue. We may seek to raise additional capital through the sale of equity securities, government grants, or debt financing; however, there is no assurance that additional financing will be available on terms favorable to us, or at all.

Off-Balance Sheet Arrangements

At June 30, 2026, we have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or entered into any non-financial agreements involving assets.

Critical Accounting Estimates

We prepare our financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statement that require estimation but are not deemed critical, as defined above. There were no changes to the Company’s critical accounting estimates from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2025.

Forward Purchase Agreement

The Company accounts for the forward purchase agreement as either equity-classified or liability-classified instruments based on an assessment of the Forward Purchase Agreement (“FPA”) specific terms and applicable authoritative guidance under FASB ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the FPA meets all of the requirements for equity classification under ASC 815, including whether the FPA is indexed to the Company’s own common shares and whether the FPA holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment is conducted at the time of FPA issuance and as of each subsequent quarterly period end date while the FPA is outstanding.

36

The Company has determined that the FPA does not meet all of the criteria for equity classification under ASC 815, as the FPA fails the fixed-for-fixed test under ASC 815-40 due to the bi-weekly Reset Price mechanism, the Dilutive Offering Reset provision, and the VWAP Trigger Event, each of which creates variability in the settlement amount that is not purely a function of the Company’s own stock price. Accordingly, the FPA is classified as a liability-classified derivative instrument, recorded at fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. The Company utilizes a Monte Carlo simulation model to determine the fair value of the FPA. The resulting fair value is recorded as a derivative liability on the condensed consolidated balance sheets. The Company records changes in the fair value of the FPA as a non-cash other income (expense) within change in fair value of derivative liabilities account on the Company’s condensed consolidated statements of operations.

Upon the issuance of shares in connection with the FPA, the Company recognizes (i) an increase to APIC measured at the fair value of the FPA at the time of share issuance, (ii) a corresponding stock subscription receivable of equal amount as a contra-equity component within stockholders’ equity (deficit), representing the present value of the consideration receivable for the shares issued, and (iii) a loss on issuance of common stock within Other Income (Expense) representing the difference between the face value of the stock subscription receivable and its present value at the issuance date. The discount between the face value and present value of the stock subscription receivable is accreted using the effective interest method over the remaining term of the FPA, with each period’s accretion recorded as an increase to both the stock subscription receivable and APIC within stockholders’ equity (deficit). The stock subscription receivable is presented as a reduction to total stockholders’ equity (deficit) and is relieved as Optional Early Termination proceeds are received from the Forward Purchase Investor.

For issued or modified FPA that meet all of the criteria for equity classification, the FPA is required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified FPAs that do not meet all of the criteria for equity classification, the FPA are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company accounts for outstanding FPA as liability-classified instrument.

The fair value of the FPA is Level 3. The determination of the fair value requires significant estimates and judgments. See Note 13 – Fair Value Measurements to the financial statements for the significant assumptions and estimates.

Changes in the significant assumptions and estimates could materially impact the valuation and the amounts recorded in the financial statements.

Recently Issued Accounting Standards

In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures by providing more detailed information about the types of expenses in commonly presented expense captions. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-10, “Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities,” which establishes comprehensive guidance under U.S. GAAP for the recognition, measurement, presentation, and disclosure of government grants received by business entities. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the effect this standard may have on its condensed consolidated financial statements and related disclosures in light of its government contract revenue activity.

In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements,” which clarifies the applicability of the interim reporting guidance, improves the organization and navigability of the interim disclosure requirements, and introduces a disclosure principle requiring entities to disclose events occurring after the most recent annual reporting period that have a material effect on the entity. The ASU is effective for public business entities for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. Entities may apply the amendments prospectively or retrospectively to any or all prior interim periods presented. The Company is currently evaluating the effect this standard may have on its condensed consolidated financial statements and related disclosures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

This item is not applicable as we are a smaller reporting company.

37

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of June 30, 2026, because of certain material weaknesses in our internal control over financial reporting, as further described below.

Notwithstanding these material weaknesses, our management concluded that our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”).

Management’s Report on Internal Control Over Financial Reporting

Material Weaknesses

A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Management identified deficiencies in the principles associated with the control environment, risk assessment, control activities, information & communication, and monitoring components of internal control, based on the criteria established by the COSO framework, that constitute material weaknesses, either individually or in the aggregate as described below.

Control Environment: Solidion does not maintain a sufficient complement of qualified technical accounting and financial reporting personnel to perform control activities, including those related to complex and/or non-routine transactions. Additionally, Solidion did not implement sufficient segregation of duties within its financial reporting function in order to demonstrate independence and proper oversight. This material weakness contributed to the additional material weaknesses further described below.

Risk Assessment: Solidion did not design and implement an effective risk assessment based on the criteria established in the COSO framework. A material weakness, either individually or in the aggregate, was identified pertaining to (i) identifying, assessing, and communicating appropriate objectives; (ii) identifying and analyzing risks to achieve these objectives; and (iii) implementing an effective risk assessment to identify and assess changes in the business if such changes were to occur.

Control Activities: Solidion did not effectively design and implement control activities to support the operating effectiveness of controls to prevent and detect potential material errors based on the criteria established in the COSO framework. As a result, the following control deficiencies constitute material weaknesses, individually or in the aggregate: (i) ineffective controls related to the review and approval of journal entries and reconciliations, and (ii) a lack of appropriate accounting policies and procedures.

Information and Communication: We identified control deficiencies that constitute material weaknesses, either individually or in the aggregate, related to (i) internal communication of information, including objectives and responsibilities for internal control, necessary to support the functioning of internal control; and (ii) communicating relevant information to external parties timely.

Monitoring: Solidion did not maintain effective monitoring activities to determine whether the components of internal control over financial reporting were present and functioning based on the criteria established in the COSO framework.

Remediation Plans and Status

We are committed to maintaining a strong internal control environment and implementing measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated as soon as practicable. We plan to engage a third party to assist in our remediation efforts. We will design and implement a risk assessment process and establish processes and controls to support an effective control environment. These actions are intended to enable Solidion to enhance our monitoring of our internal controls over financial reporting as well as enhance required communication. In addition, we will design and implement controls to address material weaknesses in control activities including the proper review and approval of journal entries and reconciliations.

As Solidion continues to evaluate its internal controls, it may take additional remediation actions. The material weaknesses will be considered remediated when Solidion’s management designs and implements effective controls that operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. Solidion’s management will monitor the effectiveness of its remediation plans and will make changes management determines to be appropriate.

Changes in Internal Control over Financial Reporting

There were no changes during the quarter ended June 30, 2026, in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

38

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The information set forth under “Litigation” in Note 6 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report is incorporated herein by reference. In June 2026, D. Boral Capital LLC (f/k/a EF Hutton LLC) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, seeking payment of outstanding principal, accrued interest, and costs under a promissory note as to which the Company is in default. See Note 6 and Note 10 to the condensed consolidated financial statements.

From time to time, the Company is involved in other legal proceedings and claims arising in the ordinary course of business. The Company does not believe any such other pending matters, individually or in the aggregate, will have a material adverse effect on its financial position, results of operations or cash flows.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

During the six months ended June 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

39

ITEM 6. EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Exhibit No. |  | Description
3.1 |  | Amended and Restated Certificate of Incorporation of Solidion Technology, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on February 8, 2024)
3.2 |  | Amended and Restated Bylaws of Solidion Technology, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on February 8, 2024)
4.1 |  | Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 8, 2026)
4.2 |  | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 8, 2026)
10.1 |  | Securities Purchase Agreement, dated June 7, 2026, by and between the Company and the investor party thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 8, 2026)
10.2 |  | Placement Agency Agreement, dated June 7, 2026, by and between the Company and Titan Partners Group LLC, a division of American Capital Partners, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 8, 2026)
10.3 |  | Waiver to Securities Purchase Agreement, dated June 7, 2026, by and between the Company, Bayside Project LLC and Madison Bond LLC (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 8, 2026)
31.1* |  | Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14(a) under the Securities and Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* |  | Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14(a) under the Securities and Exchange Act of 1934, as amended., as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1* |  | Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2* |  | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS |  | Inline XBRL Instance Document.
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document.
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* | Filed herewith

40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Solidion Technology, Inc.
Dated: August 6, 2026 | By: | /s/ Jaymes Winters
| Name: | Jaymes Winters
| Title: | Chief Executive Officer (Principal Executive Officer)

| Solidion Technology, Inc.
Dated: August 6, 2026 | By: | /s/ Vlad Prantsevich
| Name: | Vlad Prantsevich
| Title: | Chief Financial Officer (Principal Accounting and Financial Officer)

41